WO2024134381A1 - Compositions pour dispositifs ophtalmologiques - Google Patents
Compositions pour dispositifs ophtalmologiques Download PDFInfo
- Publication number
- WO2024134381A1 WO2024134381A1 PCT/IB2023/062628 IB2023062628W WO2024134381A1 WO 2024134381 A1 WO2024134381 A1 WO 2024134381A1 IB 2023062628 W IB2023062628 W IB 2023062628W WO 2024134381 A1 WO2024134381 A1 WO 2024134381A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- kit
- product
- chlorous acid
- container
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 366
- -1 chlorous acid compound Chemical class 0.000 claims abstract description 141
- 238000000034 method Methods 0.000 claims abstract description 118
- 229940077239 chlorous acid Drugs 0.000 claims abstract description 109
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 60
- 239000010452 phosphate Substances 0.000 claims abstract description 47
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical class OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 claims description 102
- 244000005700 microbiome Species 0.000 claims description 74
- 230000001954 sterilising effect Effects 0.000 claims description 67
- 238000004659 sterilization and disinfection Methods 0.000 claims description 56
- 238000004806 packaging method and process Methods 0.000 claims description 51
- 239000003638 chemical reducing agent Substances 0.000 claims description 50
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 44
- 229910001919 chlorite Inorganic materials 0.000 claims description 39
- 229910052619 chlorite group Inorganic materials 0.000 claims description 39
- 239000000017 hydrogel Substances 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 150000002978 peroxides Chemical class 0.000 claims description 34
- 229960001484 edetic acid Drugs 0.000 claims description 33
- 229920000642 polymer Polymers 0.000 claims description 33
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- 239000003974 emollient agent Substances 0.000 claims description 29
- 239000003755 preservative agent Substances 0.000 claims description 26
- 229920001296 polysiloxane Polymers 0.000 claims description 25
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 23
- 238000009472 formulation Methods 0.000 claims description 23
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 claims description 22
- 229960002218 sodium chlorite Drugs 0.000 claims description 22
- 229920002125 Sokalan® Polymers 0.000 claims description 20
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 20
- 239000004327 boric acid Substances 0.000 claims description 20
- 150000001642 boronic acid derivatives Chemical class 0.000 claims description 20
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 19
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 19
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 19
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 19
- 229910052751 metal Inorganic materials 0.000 claims description 17
- 239000002184 metal Substances 0.000 claims description 17
- 239000004359 castor oil Substances 0.000 claims description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 235000011187 glycerol Nutrition 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 235000010944 ethyl methyl cellulose Nutrition 0.000 claims description 14
- 229920003087 methylethyl cellulose Polymers 0.000 claims description 14
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 claims description 14
- 229920001206 natural gum Polymers 0.000 claims description 14
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 14
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims description 13
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 13
- 229940088644 n,n-dimethylacrylamide Drugs 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 11
- 150000002989 phenols Chemical class 0.000 claims description 11
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000004952 Polyamide Substances 0.000 claims description 10
- 150000001299 aldehydes Chemical class 0.000 claims description 10
- 229920001400 block copolymer Polymers 0.000 claims description 10
- 229920002647 polyamide Polymers 0.000 claims description 10
- 238000007789 sealing Methods 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 230000003472 neutralizing effect Effects 0.000 claims description 9
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 9
- 239000004094 surface-active agent Substances 0.000 claims description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 8
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 8
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 8
- 230000017066 negative regulation of growth Effects 0.000 claims description 8
- 229960003330 pentetic acid Drugs 0.000 claims description 8
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 7
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 7
- GRWZHXKQBITJKP-UHFFFAOYSA-L dithionite(2-) Chemical compound [O-]S(=O)S([O-])=O GRWZHXKQBITJKP-UHFFFAOYSA-L 0.000 claims description 7
- 238000010894 electron beam technology Methods 0.000 claims description 7
- QXIKMJLSPJFYOI-UHFFFAOYSA-L calcium;dichlorite Chemical compound [Ca+2].[O-]Cl=O.[O-]Cl=O QXIKMJLSPJFYOI-UHFFFAOYSA-L 0.000 claims description 6
- NWAPVVCSZCCZCU-UHFFFAOYSA-L magnesium;dichlorite Chemical compound [Mg+2].[O-]Cl=O.[O-]Cl=O NWAPVVCSZCCZCU-UHFFFAOYSA-L 0.000 claims description 6
- VISKNDGJUCDNMS-UHFFFAOYSA-M potassium;chlorite Chemical group [K+].[O-]Cl=O VISKNDGJUCDNMS-UHFFFAOYSA-M 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 5
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 5
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 5
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 5
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 5
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- 229910052783 alkali metal Inorganic materials 0.000 claims description 5
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 5
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims description 5
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 5
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 5
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 5
- OIGHMJXGUZVPOV-NSHDSACASA-N methyl (2S)-3-(4-hydroxyphenyl)-2-(prop-2-enoylamino)propanoate Chemical compound COC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)C=C OIGHMJXGUZVPOV-NSHDSACASA-N 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 5
- CHKKZILXOJVMAD-UHFFFAOYSA-N 2-(benzotriazol-2-yl)-4-(2-hydroxyethyl)phenol Chemical compound OCCC1=CC=C(O)C(N2N=C3C=CC=CC3=N2)=C1 CHKKZILXOJVMAD-UHFFFAOYSA-N 0.000 claims description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- 101100080807 Drosophila melanogaster mt:ND2 gene Proteins 0.000 claims description 4
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical group [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 4
- 101150016680 MT-ND2 gene Proteins 0.000 claims description 4
- 102100028488 NADH-ubiquinone oxidoreductase chain 2 Human genes 0.000 claims description 4
- 101150102231 ND2 gene Proteins 0.000 claims description 4
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 4
- 229960004308 acetylcysteine Drugs 0.000 claims description 4
- 125000002015 acyclic group Chemical group 0.000 claims description 4
- 229940072107 ascorbate Drugs 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 4
- YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical compound [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 4
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 claims description 4
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 claims description 4
- 239000004584 polyacrylic acid Substances 0.000 claims description 4
- 229920000570 polyether Polymers 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 229940068965 polysorbates Drugs 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 230000003385 bacteriostatic effect Effects 0.000 abstract description 9
- 239000000243 solution Substances 0.000 description 67
- 239000000047 product Substances 0.000 description 50
- 235000021317 phosphate Nutrition 0.000 description 47
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 29
- 238000012360 testing method Methods 0.000 description 29
- 150000001875 compounds Chemical class 0.000 description 22
- 241001331781 Aspergillus brasiliensis Species 0.000 description 20
- 239000012449 sabouraud dextrose agar Substances 0.000 description 18
- 239000006150 trypticase soy agar Substances 0.000 description 18
- 230000000813 microbial effect Effects 0.000 description 16
- 230000009467 reduction Effects 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 15
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- WQZGKKKJIJFFOK-ZZWDRFIYSA-N L-glucose Chemical compound OC[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-ZZWDRFIYSA-N 0.000 description 13
- 238000003860 storage Methods 0.000 description 12
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 11
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- QBWCMBCROVPCKQ-UHFFFAOYSA-M chlorite Chemical compound [O-]Cl=O QBWCMBCROVPCKQ-UHFFFAOYSA-M 0.000 description 10
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 10
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 10
- 235000012141 vanillin Nutrition 0.000 description 10
- 241000222122 Candida albicans Species 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 230000002906 microbiologic effect Effects 0.000 description 9
- 230000007935 neutral effect Effects 0.000 description 9
- 239000002997 ophthalmic solution Substances 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 9
- 244000063299 Bacillus subtilis Species 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 8
- 229940095731 candida albicans Drugs 0.000 description 8
- 229960005091 chloramphenicol Drugs 0.000 description 8
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 8
- 229920001577 copolymer Polymers 0.000 description 8
- 229940054534 ophthalmic solution Drugs 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 229940083542 sodium Drugs 0.000 description 8
- 241001446304 Fusarium keratoplasticum Species 0.000 description 7
- 108010024636 Glutathione Proteins 0.000 description 7
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 7
- 239000003889 eye drop Substances 0.000 description 7
- 229960003180 glutathione Drugs 0.000 description 7
- 229920003023 plastic Polymers 0.000 description 7
- 239000004033 plastic Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 5
- 150000003935 benzaldehydes Chemical class 0.000 description 5
- 229940005993 chlorite ion Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 229920003169 water-soluble polymer Polymers 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
- 244000303769 Amaranthus cruentus Species 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 241000220317 Rosa Species 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 229960000686 benzalkonium chloride Drugs 0.000 description 4
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 4
- 229940105329 carboxymethylcellulose Drugs 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000009931 harmful effect Effects 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000004255 ion exchange chromatography Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 4
- 239000004417 polycarbonate Substances 0.000 description 4
- 229920000515 polycarbonate Polymers 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920001616 Polymacon Polymers 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000002861 polymer material Substances 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 3
- ISPFRDAWONQRSH-JTQLQIEISA-N (2s)-3-(4-hydroxyphenyl)-2-(prop-2-enoylamino)propanoic acid Chemical compound C=CC(=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 ISPFRDAWONQRSH-JTQLQIEISA-N 0.000 description 2
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 2
- MMWFQFGXFPTUIF-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one 2-hydroxyethyl 2-methylprop-2-enoate 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate prop-2-enyl 2-methylprop-2-enoate Chemical compound C=CN1CCCC1=O.CC(=C)C(=O)OCCO.CC(=C)C(=O)OCC=C.CC(=C)C(=O)OCCOC(=O)C(C)=C MMWFQFGXFPTUIF-UHFFFAOYSA-N 0.000 description 2
- JYYNAJVZFGKDEQ-UHFFFAOYSA-N 2,4-Dimethylpyridine Chemical class CC1=CC=NC(C)=C1 JYYNAJVZFGKDEQ-UHFFFAOYSA-N 0.000 description 2
- UURVHRGPGCBHIC-UHFFFAOYSA-N 3-(ethenoxycarbonylamino)propanoic acid 4-[[[[[[[[[[[[[[[[[[[[[[[[[[[4-ethenoxycarbonyloxybutyl(dimethyl)silyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]butyl ethenyl carbonate 1-ethenylpyrrolidin-2-one ethenyl N-[3-tris(trimethylsilyloxy)silylpropyl]carbamate Chemical compound C=CN1CCCC1=O.OC(=O)CCNC(=O)OC=C.C[Si](C)(C)O[Si](CCCNC(=O)OC=C)(O[Si](C)(C)C)O[Si](C)(C)C.C[Si](C)(CCCCOC(=O)OC=C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)CCCCOC(=O)OC=C UURVHRGPGCBHIC-UHFFFAOYSA-N 0.000 description 2
- ZOPSJJCUEOEROC-NSQCPRBHSA-N 3-[[butyl(dimethyl)silyl]oxy-dimethylsilyl]propyl 2-methylprop-2-enoate;n,n-dimethylprop-2-enamide;1-ethenylpyrrolidin-2-one;2-hydroxyethyl 2-methylprop-2-enoate;[(2r)-2-hydroxy-3-[3-[methyl-bis(trimethylsilyloxy)silyl]propoxy]propyl] 2-methylprop-2-enoat Chemical compound CN(C)C(=O)C=C.C=CN1CCCC1=O.CC(=C)C(=O)OCCO.CC(=C)C(=O)OCCOC(=O)C(C)=C.CCCC[Si](C)(C)O[Si](C)(C)CCCOC(=O)C(C)=C.CC(=C)C(=O)OC[C@H](O)COCCC[Si](C)(O[Si](C)(C)C)O[Si](C)(C)C ZOPSJJCUEOEROC-NSQCPRBHSA-N 0.000 description 2
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical class CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 2
- 241001550224 Apha Species 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical class O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- 206010015946 Eye irritation Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 239000004695 Polyether sulfone Substances 0.000 description 2
- 239000004697 Polyetherimide Substances 0.000 description 2
- 229920000289 Polyquaternium Polymers 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical class C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 2
- NGMTUCFCIUGWAG-UHFFFAOYSA-L [Cu+2].[O-]Cl=O.[O-]Cl=O Chemical compound [Cu+2].[O-]Cl=O.[O-]Cl=O NGMTUCFCIUGWAG-UHFFFAOYSA-L 0.000 description 2
- BXGLFSWHULONLR-UHFFFAOYSA-M [O-][Cl]=O.CC[P+](CC)(CC)c1ccc(cc1[N+]([O-])=O)[N+]([O-])=O Chemical compound [O-][Cl]=O.CC[P+](CC)(CC)c1ccc(cc1[N+]([O-])=O)[N+]([O-])=O BXGLFSWHULONLR-UHFFFAOYSA-M 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- YUUVAZCKXDQEIS-UHFFFAOYSA-N azanium;chlorite Chemical compound [NH4+].[O-]Cl=O YUUVAZCKXDQEIS-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- QVHNCCYHVOFJRY-UHFFFAOYSA-L calcium dichlorite trihydrate Chemical compound O.O.O.[Ca+2].[O-]Cl=O.[O-]Cl=O QVHNCCYHVOFJRY-UHFFFAOYSA-L 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008380 degradant Substances 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- QYQIKTBQNRWCEW-UHFFFAOYSA-K dichlorosyloxyalumanyl chlorite Chemical compound [Al+3].[O-]Cl=O.[O-]Cl=O.[O-]Cl=O QYQIKTBQNRWCEW-UHFFFAOYSA-K 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical class NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 231100000013 eye irritation Toxicity 0.000 description 2
- 238000013100 final test Methods 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 150000004688 heptahydrates Chemical class 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- BVVBTRGSXXWJLG-UHFFFAOYSA-L magnesium dichlorite trihydrate Chemical compound O.O.O.[Mg+2].[O-]Cl=O.[O-]Cl=O BVVBTRGSXXWJLG-UHFFFAOYSA-L 0.000 description 2
- 150000003956 methylamines Chemical class 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- PNLUGRYDUHRLOF-UHFFFAOYSA-N n-ethenyl-n-methylacetamide Chemical compound C=CN(C)C(C)=O PNLUGRYDUHRLOF-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 125000006353 oxyethylene group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- FXLOVSHXALFLKQ-UHFFFAOYSA-N para-methylbenzaldehyde Natural products CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 150000004714 phosphonium salts Chemical group 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 229920001707 polybutylene terephthalate Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920006393 polyether sulfone Polymers 0.000 description 2
- 229920001601 polyetherimide Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920000306 polymethylpentene Polymers 0.000 description 2
- 239000011116 polymethylpentene Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229920013730 reactive polymer Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000001507 sample dispersion Methods 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 125000005373 siloxane group Chemical group [SiH2](O*)* 0.000 description 2
- NLAIHECABDOZBR-UHFFFAOYSA-M sodium 2,2-bis(2-methylprop-2-enoyloxymethyl)butyl 2-methylprop-2-enoate 2-hydroxyethyl 2-methylprop-2-enoate 2-methylprop-2-enoate Chemical compound [Na+].CC(=C)C([O-])=O.CC(=C)C(=O)OCCO.CCC(COC(=O)C(C)=C)(COC(=O)C(C)=C)COC(=O)C(C)=C NLAIHECABDOZBR-UHFFFAOYSA-M 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- OMIBJNSNJCZSPU-UHFFFAOYSA-M sodium;chlorite;trihydrate Chemical compound O.O.O.[Na+].[O-]Cl=O OMIBJNSNJCZSPU-UHFFFAOYSA-M 0.000 description 2
- MWNQXXOSWHCCOZ-UHFFFAOYSA-L sodium;oxido carbonate Chemical compound [Na+].[O-]OC([O-])=O MWNQXXOSWHCCOZ-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000028070 sporulation Effects 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- FDXKBUSUNHRUIZ-UHFFFAOYSA-M tetramethylazanium;chlorite Chemical compound [O-]Cl=O.C[N+](C)(C)C FDXKBUSUNHRUIZ-UHFFFAOYSA-M 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical class CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- DYWNLSQWJMTVGJ-UHFFFAOYSA-N (1-hydroxy-1-phenylpropan-2-yl)azanium;chloride Chemical compound Cl.CC(N)C(O)C1=CC=CC=C1 DYWNLSQWJMTVGJ-UHFFFAOYSA-N 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical class C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- UICXTANXZJJIBC-UHFFFAOYSA-N 1-(1-hydroperoxycyclohexyl)peroxycyclohexan-1-ol Chemical compound C1CCCCC1(O)OOC1(OO)CCCCC1 UICXTANXZJJIBC-UHFFFAOYSA-N 0.000 description 1
- GNTAAQBKCCJXGF-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one methyl 2-methylprop-2-enoate 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate prop-2-enyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.C=CN1CCCC1=O.CC(=C)C(=O)OCC=C.CC(=C)C(=O)OCCOC(=O)C(C)=C GNTAAQBKCCJXGF-UHFFFAOYSA-N 0.000 description 1
- SVKHOOHZPMBIGM-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;2-hydroxyethyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.C=CN1CCCC1=O.CC(=C)C(=O)OCCO SVKHOOHZPMBIGM-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Chemical class OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XPSXBEJFSQZTBS-UHFFFAOYSA-N 2,2-bis(2-methylprop-2-enoyloxymethyl)butyl 2-methylprop-2-enoate 2-hydroxyethyl 2-methylprop-2-enoate N-(2-methyl-4-oxopentan-2-yl)prop-2-enamide Chemical compound CC(=C)C(=O)OCCO.CC(=O)CC(C)(C)NC(=O)C=C.CCC(COC(=O)C(C)=C)(COC(=O)C(C)=C)COC(=O)C(C)=C XPSXBEJFSQZTBS-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 1
- WFUGQJXVXHBTEM-UHFFFAOYSA-N 2-hydroperoxy-2-(2-hydroperoxybutan-2-ylperoxy)butane Chemical compound CCC(C)(OO)OOC(C)(CC)OO WFUGQJXVXHBTEM-UHFFFAOYSA-N 0.000 description 1
- KKOWZRLUUCIGQY-UHFFFAOYSA-N 2-hydroxyethyl 2-methylprop-2-enoate 2-methylprop-2-enoic acid 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(O)=O.CC(=C)C(=O)OCCO.CC(=C)C(=O)OCCOC(=O)C(C)=C KKOWZRLUUCIGQY-UHFFFAOYSA-N 0.000 description 1
- PVISMVGVPWOQMG-UHFFFAOYSA-N 2-hydroxyethyl 2-methylprop-2-enoate;2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCO.CC(=C)C(=O)OCCOC(=O)C(C)=C PVISMVGVPWOQMG-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical class OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- QGBLCIBATKETJC-UHFFFAOYSA-N 3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane;manganese(2+) Chemical compound [Mn+2].O1B([O-])OB2OB([O-])OB1O2 QGBLCIBATKETJC-UHFFFAOYSA-N 0.000 description 1
- OBNZPZAOTISUNM-UHFFFAOYSA-N 4-chloro-1,6-dimethylcyclohexa-2,4-dien-1-ol Chemical compound ClC1=CC(C(C=C1)(C)O)C OBNZPZAOTISUNM-UHFFFAOYSA-N 0.000 description 1
- RHPUJHQBPORFGV-UHFFFAOYSA-N 4-chloro-2-methylphenol Chemical compound CC1=CC(Cl)=CC=C1O RHPUJHQBPORFGV-UHFFFAOYSA-N 0.000 description 1
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical class O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 239000004343 Calcium peroxide Substances 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical class OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229930091371 Fructose Chemical class 0.000 description 1
- 239000005715 Fructose Chemical class 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical class OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- SPAGIJMPHSUYSE-UHFFFAOYSA-N Magnesium peroxide Chemical compound [Mg+2].[O-][O-] SPAGIJMPHSUYSE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N Methyl ethyl ketone Natural products CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
- LDFOWBBPEBRKRQ-UHFFFAOYSA-L O.O.[Ba++].[O-][Cl]=O.[O-][Cl]=O Chemical compound O.O.[Ba++].[O-][Cl]=O.[O-][Cl]=O LDFOWBBPEBRKRQ-UHFFFAOYSA-L 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920000688 Poly[(2-ethyldimethylammonioethyl methacrylate ethyl sulfate)-co-(1-vinylpyrrolidone)] Polymers 0.000 description 1
- 229920001090 Polyaminopropyl biguanide Polymers 0.000 description 1
- 229920002413 Polyhexanide Polymers 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 229920003082 Povidone K 90 Polymers 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Chemical class OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L Zinc chloride Inorganic materials [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
- WOHVONCNVLIHKY-UHFFFAOYSA-L [Ba+2].[O-]Cl=O.[O-]Cl=O Chemical compound [Ba+2].[O-]Cl=O.[O-]Cl=O WOHVONCNVLIHKY-UHFFFAOYSA-L 0.000 description 1
- COKQEGDMCJNDMF-UHFFFAOYSA-L [Mn+2].[O-]Cl=O.[O-]Cl=O Chemical compound [Mn+2].[O-]Cl=O.[O-]Cl=O COKQEGDMCJNDMF-UHFFFAOYSA-L 0.000 description 1
- FENRSEGZMITUEF-ATTCVCFYSA-E [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OP(=O)([O-])O[C@@H]1[C@@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H]1OP(=O)([O-])[O-] Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OP(=O)([O-])O[C@@H]1[C@@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H]1OP(=O)([O-])[O-] FENRSEGZMITUEF-ATTCVCFYSA-E 0.000 description 1
- GUCYFKSBFREPBC-UHFFFAOYSA-N [phenyl-(2,4,6-trimethylbenzoyl)phosphoryl]-(2,4,6-trimethylphenyl)methanone Chemical compound CC1=CC(C)=CC(C)=C1C(=O)P(=O)(C=1C=CC=CC=1)C(=O)C1=C(C)C=C(C)C=C1C GUCYFKSBFREPBC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229920006322 acrylamide copolymer Polymers 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 150000008045 alkali metal halides Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Chemical class OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical class OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium peroxydisulfate Substances [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 1
- VAZSKTXWXKYQJF-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)OOS([O-])=O VAZSKTXWXKYQJF-UHFFFAOYSA-N 0.000 description 1
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Chemical class OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ZJRXSAYFZMGQFP-UHFFFAOYSA-N barium peroxide Chemical compound [Ba+2].[O-][O-] ZJRXSAYFZMGQFP-UHFFFAOYSA-N 0.000 description 1
- HUMNYLRZRPPJDN-KWCOIAHCSA-N benzaldehyde Chemical group O=[11CH]C1=CC=CC=C1 HUMNYLRZRPPJDN-KWCOIAHCSA-N 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Chemical class OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical class OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- LHJQIRIGXXHNLA-UHFFFAOYSA-N calcium peroxide Chemical compound [Ca+2].[O-][O-] LHJQIRIGXXHNLA-UHFFFAOYSA-N 0.000 description 1
- 235000019402 calcium peroxide Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229940078916 carbamide peroxide Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940119743 dextran 70 Drugs 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 238000013154 diagnostic monitoring Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- MSJMDZAOKORVFC-UAIGNFCESA-L disodium maleate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C/C([O-])=O MSJMDZAOKORVFC-UAIGNFCESA-L 0.000 description 1
- YMGGAHMANIOXGP-UHFFFAOYSA-L disodium;oxido sulfate Chemical compound [Na+].[Na+].[O-]OS([O-])(=O)=O YMGGAHMANIOXGP-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- FXPHJTKVWZVEGA-UHFFFAOYSA-N ethenyl hydrogen carbonate Chemical class OC(=O)OC=C FXPHJTKVWZVEGA-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical class C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 229930182830 galactose Chemical class 0.000 description 1
- 239000007863 gel particle Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000004313 glare Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 208000027136 gram-positive bacterial infections Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- DLINORNFHVEIFE-UHFFFAOYSA-N hydrogen peroxide;zinc Chemical compound [Zn].OO DLINORNFHVEIFE-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 229940113174 imidurea Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Chemical class 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- HPGPEWYJWRWDTP-UHFFFAOYSA-N lithium peroxide Chemical compound [Li+].[Li+].[O-][O-] HPGPEWYJWRWDTP-UHFFFAOYSA-N 0.000 description 1
- KAGBQTDQNWOCND-UHFFFAOYSA-M lithium;chlorite Chemical compound [Li+].[O-]Cl=O KAGBQTDQNWOCND-UHFFFAOYSA-M 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960004995 magnesium peroxide Drugs 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000012569 microbial contaminant Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002637 mydriatic agent Substances 0.000 description 1
- 230000002911 mydriatic effect Effects 0.000 description 1
- WFKDPJRCBCBQNT-UHFFFAOYSA-N n,2-dimethylprop-2-enamide Chemical compound CNC(=O)C(C)=C WFKDPJRCBCBQNT-UHFFFAOYSA-N 0.000 description 1
- RQAKESSLMFZVMC-UHFFFAOYSA-N n-ethenylacetamide Chemical compound CC(=O)NC=C RQAKESSLMFZVMC-UHFFFAOYSA-N 0.000 description 1
- LRDKXGNUEGNSIK-UHFFFAOYSA-L nickel(2+) dichlorite dihydrate Chemical compound O.O.[Ni+2].[O-]Cl=O.[O-]Cl=O LRDKXGNUEGNSIK-UHFFFAOYSA-L 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000000621 oxo-lambda(3)-chloranyloxy group Chemical group *OCl=O 0.000 description 1
- 125000005430 oxychloro group Chemical group 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229940093424 polyaminopropyl biguanide Drugs 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229960003548 polymyxin b sulfate Drugs 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical class [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004515 progressive myopia Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Chemical class 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical class O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- NVMLBGDGWYDOBZ-UHFFFAOYSA-M silver;chlorite Chemical compound [Ag+].[O-]Cl=O NVMLBGDGWYDOBZ-UHFFFAOYSA-M 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical class [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Chemical class 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229960001922 sodium perborate Drugs 0.000 description 1
- PFUVRDFDKPNGAV-UHFFFAOYSA-N sodium peroxide Chemical compound [Na+].[Na+].[O-][O-] PFUVRDFDKPNGAV-UHFFFAOYSA-N 0.000 description 1
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 1
- 229940083982 sodium phytate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Chemical class 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- UHCGLDSRFKGERO-UHFFFAOYSA-N strontium peroxide Chemical compound [Sr+2].[O-][O-] UHCGLDSRFKGERO-UHFFFAOYSA-N 0.000 description 1
- 150000003440 styrenes Chemical class 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical class [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000001585 trabecular meshwork Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- VLCLHFYFMCKBRP-UHFFFAOYSA-N tricalcium;diborate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]B([O-])[O-].[O-]B([O-])[O-] VLCLHFYFMCKBRP-UHFFFAOYSA-N 0.000 description 1
- NFMWFGXCDDYTEG-UHFFFAOYSA-N trimagnesium;diborate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]B([O-])[O-].[O-]B([O-])[O-] NFMWFGXCDDYTEG-UHFFFAOYSA-N 0.000 description 1
- WUUHFRRPHJEEKV-UHFFFAOYSA-N tripotassium borate Chemical compound [K+].[K+].[K+].[O-]B([O-])[O-] WUUHFRRPHJEEKV-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- LVLANIHJQRZTPY-UHFFFAOYSA-N vinyl carbamate Chemical class NC(=O)OC=C LVLANIHJQRZTPY-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- IDDWAHTYORBPCQ-UHFFFAOYSA-L zinc dichlorite dihydrate Chemical compound O.O.[Zn+2].[O-]Cl=O.[O-]Cl=O IDDWAHTYORBPCQ-UHFFFAOYSA-L 0.000 description 1
- 229940105296 zinc peroxide Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/086—Container, accessories or devices therefor
Definitions
- compositions of the present invention are also disclosed.
- BACKGROUND OF THE INVENTION Contact lenses are generally provided to consumers as individually packaged products.
- the single unit containers which package such contact lenses typically use buffered saline as storage or packaging solutions.
- Such packaging solutions should provide for, at least in some cases, a short-term period – e.g., between solution preparation and sterilization of the end-staged packaged product - an environment that does not facilitate the growth of harmful or undesirable microorganisms.
- undesirable microorganisms include Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans, Bacillus subtilis and Aspergillus brasiliensis.
- the packaging solutions should be gentle to the eye since at least some of the packaging solution will, most likely, remain on a contact lens once it is removed from the packaging solution and placed directly on (i.e., by direct application to) the eye.
- the contact lens (or other ophthalmic device) packaging solution should also be compatible with the materials forming the contact lens (or other ophthalmic device) and the contact lens packaging.
- a challenge in preparing packaging solutions for ophthalmic devices is formulating solutions which do not negatively affect eye comfort or the solution’s compatibility with the material(s) forming the ophthalmic device.
- ophthalmic compositions which helps to maintain the pH of the composition within an acceptable physiological range.
- Phosphates are known to be capable buffers, but, unfortunately, phosphates are also known promoters of microbial growth.
- bacteriostatic compositions e.g., packaging solutions
- buffered solutions can be achieved by combining chlorous acid compounds with phosphates at specific ratios of chlorous acid compounds to phosphates buffers – as detailed below.
- Figure 1 is reproduction of “Influence of concentration of phosphate on NaCl effect on phosphate pH” illustration from Robinson, H., W., The Influence of Neutral Salts on the pH of Phosphate Buffer Mixtures, J. Biol. Chem., LXXXII (3), 775-802, (1929)).
- Figure 2 is a graph showing the microbial log reduction for test microorganisms at Days 0-3 when using a composition of the present invention.
- Figure 3 is a graph showing percent (%) microbial population count reduction for test microorganisms at Day 3 when using a composition of the present invention.
- Figures 4A-E are graphs showing the microbial population count for test microorganisms in the composition of Example 2 over time.
- Figures 5-7 are graphs showing the inhibition of growth of the yeast Candida albicans, the fungus Aspergillus brasiliensis and the bacteria Bacillus subtilis – subspecies spizizenii, 2 Docket No. VTN6124WOPCT1 respectively, when each microorganism was spiked into the composition of Table 8 containing varying concentrations of chlorite.
- a sealed ophthalmologic product or kit comprising: a) a composition for storing contact lenses as an admixture or mixture: i.
- a chlorous acid compound in an amount effective to inhibit the growth of microorganisms in the composition; ii. a phosphate compound buffer; iii. optionally, a reductant for neutralizing the chlorous acid compound, provided that, after the reductant’s admixture to the composition, the chlorous acid compound remains effective to inhibit the growth of microorganisms in the composition for a period of time; and iv. an ophthalmologically acceptable carrier comprising one or more tonicity agents at least one contact lens sealed in a container with the composition and b) a container comprising a sealed compartment comprising at least one contact lens in the presence of the composition.
- the present invention also relates to a method of inhibiting the growth of microorganisms in a composition for a period of time occurring from preparation of the composition to sterilization of the composition in sealed a container, comprising the steps of: a. mixing a composition comprising: 3 Docket No. VTN6124WOPCT1 i. a chlorous acid compound in an amount effective to inhibit the growth of microorganisms in the composition; ii. a phosphate compound buffer; and iii. optionally, a reductant for neutralizing the chlorous acid compound after admixture to the composition ; b. storing the composition for the period of time during which time there is an inhibition of growth of microorganisms; c. placing the composition in a container; d.
- a composition comprising: 3 Docket No. VTN6124WOPCT1 i. a chlorous acid compound in an amount effective to inhibit the growth of microorganisms in the composition; ii. a phosphate compound buffer; and
- the present invention further relates to a method of packaging and sterilizing a composition in sealed a container, comprising the steps of: a. mixing a composition comprising: i. a chlorous acid compound in an amount effective to inhibit the growth of microorganisms in the composition; ii.
- a phosphate compound buffer iii. optionally, a reductant for neutralizing the chlorous acid compound after admixture to the composition
- b. placing the composition in a container c. sealing the container of step b.; d. sterilizing the container of the c. 4 Docket No. VTN6124WOPCT1 optionally, wherein the composition is free of or substantially free of one or more of boric acid, borates, non-chlorous acid preservatives, peroxides (e.g., hydrogen peroxide) or sources of peroxides, persulfates, carboxy vinyl polymers, natural gums, glycerin, polyoxyethylene-castor oil and derivatives thereof.
- peroxides e.g., hydrogen peroxide
- sources of peroxides, persulfates carboxy vinyl polymers, natural gums, glycerin, polyoxyethylene-castor oil and derivatives thereof.
- the present invention also relates to methods of making and using the disclosed compositions.
- DETAILED DESCRIPTION OF THE INVENTION As indicated above, the present invention relates to compositions comprising one or more chlorous acid compounds and one or more phosphate compound as an ophthalmologically acceptable carrier.
- the compositions may be useful for storing or as a packaging solution for ophthalmic devices.
- the present invention provides ophthalmic solutions comprising a transient microbial growth inhibiting compound that is bacteriostatic from the formulation of the composition through heat sterilization, such as autoclaving, but substantially or entirely neutralized during sterilization providing a non-preserved ophthalmic solution after sterilization.
- the present invention further provided hermetically sealed contact lens packages comprising a contact lens and an ophthalmic solution of the present invention.
- the compositions may be useful for direct application to the eyes for an eye care benefit such as relieving eye discomfort.
- the compositions and methods of the present invention can comprise, consist of, or consist essentially of the steps, essential elements and limitations of the invention described herein, as well any of the additional or optional ingredients, components, or limitations described herein.
- the term “comprising” (and its grammatical variations) as used herein is used in the inclusive sense of “having” or “including” and not in the exclusive sense of “consisting only of.”
- the terms “a” and “the” as used herein are understood to encompass the plural as well as the singular. 5 Docket No.
- VTN6124WOPCT1 Unless otherwise indicated, all documents cited are incorporated herein by reference. Furthermore, all documents incorporated herein by reference are only incorporated herein to the extent that they are not inconsistent with this specification. The citation of any document is not to be construed as an admission that it is prior art with response to the present invention. The present invention as disclosed herein may be practiced in the absence of any compound or element (or group of compounds or elements) which is not specifically disclosed herein.
- pharmaceutically acceptable means biologically tolerable, and otherwise biologically suitable for application or exposure to the eyes and surrounding tissues of the eyes without undue adverse effects such as toxicity, irritation, allergic response and the like.
- ophthalmically acceptable and/or compatible means the composition or component(s) is pharmaceutically acceptable and is not or substantially is not, detrimental, negative, or harmful to any part of the eye (or surrounding tissues) or the other ingredients (including actives) in the composition itself.
- water soluble means that the components, either alone or in combination with other components, do not form precipitates or gel particles visible to the human eye at the concentrations selected and across the temperatures and pH regimes common for manufacturing, sterilizing and storing the ophthalmic solution.
- cationic preservatives means net positively charged compounds having antimicrobial properties and include, without limitation thereto, one or more of polymyxin B sulfate, quaternary ammonium compounds, poly(quaternary ammonium) compounds, benzalkonium chloride, cetylpridinium chloride, benzethonium chloride, cetyltrimethyl ammonium bromide, chlorhexidine, poly(hexamethylene biguanide), and mixtures thereof.
- Poly(quaternary ammonium) compounds are compounds that are positively charged surface active agents (i.e., cationic surfactants ) which act to compromise the cell walls and membranes , and examples include BUSAN 77, ONAMERM, MIRAPOLA15, IONENES A, 6 Docket No. VTN6124WOPCT1 POLYQUATERNIUM 11, POLYQUATER NIUM 7, BRADOSOL, AND POLYQUAT D-17- 1742.
- the term “effective to inhibit”, as used herein means an amount which causes an inhibition in the growth of microorganisms.
- the term “lidstock”, as used herein means, a flexible film or sheet which is heat sealed to the concave side of the plastic blister packaging to form a sealed cavity.
- Lidstock is generally multilayered and comprises a support layer and a peelable seal layer.
- the lidstock may further comprise additional layers including print layers, lamination layers, foil layers and combinations thereof and the like.
- the term “inhibition of growth of microorganisms” in the composition occurs where, and means that, there is a less than a 0.5 log, less than 0.3 log, less than 0.2 log, increase, or no increase in the count of any microorganism present in the composition after 1 day, 2 days, 3 days, 5 days, 7 days, 8 days, 10 days, 13 days, 14 days, 15 days, 20 days, 21 days or 22 days from date of preparation of the compositions of the present invention.
- hydrogels means polymeric networks that swell in water or aqueous solutions, typically absorbing at least 10 weight percent water.
- Silicone hydrogels are hydrogels that are made from at least one silicone-containing component with at least one hydrophilic component. Hydrophilic components may also include non-reactive polymers. All percentages, parts and ratios are based upon the total weight of the composition of the present invention, unless otherwise specified. All such weights as they pertain to the listed ingredients are based on the active level and, therefore, do not include carriers or by-products that may be included in commercially available materials, unless otherwise specified.
- the Chlorous Acid Compound The compositions of the present invention, at the time of mixing, comprise one or more chlorous acid compounds or salts thereof.
- the chlorous acid compounds and salts thereof are ophthalmically compatible with the eyes and surrounding tissue and are compatible with the ingredients in compositions of the present invention. Upon degradation (e.g., sterilization or 7 Docket No. VTN6124WOPCT1 storage conditions), the chlorous acid compounds and salts degrade to ophthalmically compatible degradants.
- the degradants of chlorous acid compounds and salts thereof do not interact with the contact lens stored or packaged therewith nor the storage/packaging containers (including the lidstock).
- the chlorous acid compound may be an anhydride or a hydrate.
- the salts of chlorous acid may be a mono or a double salt.
- chlorous acid compounds suitable for use in the compositions or methods of the present invention include (selected from or selected from the group consisting of), but are not limited to, chlorous acid; an alkali metal salt of chlorous acid including lithium chlorite, sodium chlorite, sodium chlorite trihydrate, or potassium chlorite and the like; an alkali earth metal salt of chlorous acid including magnesium chlorite, magnesium chlorite trihydrate, calcium chlorite, calcium chlorite trihydrate, barium chlorite, or barium chlorite dihydrate and the like; an earth metal salt of chlorous acid such as aluminum chlorite; a zinc-family salt of chlorous acid such as zinc chlorite dihydrate; a transitional metal salt of chlorous acid such as copper chlorite (II), copper chlorite (III), silver chlorite, nickel chlorite dihydrate or manganese chlorite; ammonium chlorite; a quaternary ammonium salt of chlorous acid such as tetramethylammonium chlorite; a quatern
- compositions of the present invention are sources of chlorous acid compounds such as stabilized oxychloro complex, (Purite, Bio-Cide International Inc., Ok, USA) and/or stabilized chlorite peroxide (SOC - Oxyd Tubilux.). Mixtures of any the above-mentioned chlorous acid compounds or sources of chlorous acid compounds may also be used.
- Salts of chlorous acid compounds which are particularly preferred for use herein are ophthalmically compatible salts including but not limited to, sodium chlorite, sodium chlorite trihydrate, or potassium chlorite and the like; an alkali earth metal salt of chlorous acid including magnesium chlorite, magnesium chlorite trihydrate, calcium chlorite, calcium chlorite trihydrate, 8 Docket No.
- Chlorite compounds suitable for use in the present invention include chlorite compounds and salts thereof, including (selected from or selected from the group consisting of), but are not limited to, water soluble alkali metal chlorites, water soluble alkaline metal chlorites and mixtures thereof.
- Specific examples of chlorite compounds include (selected from or selected from the group consisting of) potassium chlorite, sodium chlorite, calcium chlorite, magnesium chlorite and mixtures thereof.
- the chlorite compound comprises sodium chlorite.
- the chlorous acid compound is incorporated into the compositions of the present invention to provide bacteriostatic properties for inhibiting microbial growth in the compositions.
- the bacteriostatic properties for inhibiting microbial growth may occur for and are in effect during a period of time, which may be from the preparation or manufacture of the compositions of the present invention up to the time of performing at least one sterilization method on the composition, which may be sterilization of the composition in a sealed package with at least one contact lens as described below.
- the period of time period may be up to two weeks, during which the solution is stored in a sealed container at ambient temperature.
- the chlorous acid compound concentration is substantially or entirely neutralized, for example by at least about 50%, about 70%, about 80%, about 90% or 100% neutralized.
- concentrations for the chlorous acid compound include concentrations from 0.0020% (or about 0.0020%) to 0.2000% (or about 0.2000%), or from 0.0020% (or about 0.0020%) to 0.1000% (or about 0.1000%), or from 0.0050% (or about 0.0050%) to 0.1000% (or about 0.1000%), or from 0.0075% (or about 0.0075%) to 0.1000% (or about 0.1000%), or from 9 Docket No.
- VTN6124WOPCT1 0.0080% (or about 0.0080%) to 0.0500% (or about 0.0500%), or from 0.0090% (or about 0.0090%) to 0.0200% (or about 0.0200%), or from 0.0095% (or about 0.0095%) to 0.0150% (or about 0.0150%), or 0.01% (or about 0.01%), based on the total weight of the composition upon formulation.
- the chlorous acid compound provides chlorite anion concentrations of from 0.0015% (or about 0.0015%) to 0.1500% (or about 0.1500%), or from 0.0015% (or about 0.0015%) to 0.0750% (or about 0.0750%), or from 0.0037% (or about 0.0037%) to 0.0750% (or about 0.0750%), or from 0.0056% (or about 0.0056%) to 0.0750% (or about 0.0750%), or from 0.0060% (or about 0.0060%) to 0.0370% (or about 0.0370%), or from 0.0067% (or about 0.0067%) to 0.0150% (or about 0.0150%), or from 0.0071% (or about 0.0071%) to 0.0110% (or about 0.0110%), based on the total weight of the composition upon formulation.
- period of time as used in association with the bacteriostatic properties of the chlorous acid compound, it is meant up to or at least one day, two days, three days, four days, five days , six days, seven days eight days, ten days, twelve days, fourteen days, fifteen days, 18 days, 20 days, 21 days or 22 days from date of preparation of the compositions of the present invention.
- the period of time may be up two weeks, during which the solution is stored in a sealed container at ambient temperature.
- the Phosphate Compound The compositions of the present invention, at the time of mixing, comprise a phosphate compound.
- phosphate shall refer to phosphoric acid, anions and/or salts of phosphoric acid and other pharmaceutically acceptable phosphates, or combinations thereof. Suitable phosphates may be incorporated as one or more monobasic phosphates, dibasic phosphates and the like. Examples of phosphate compounds useful in the compositions are those selected from pharmaceutically acceptable phosphate salts of alkali and/or alkaline earth metals.
- the phosphate compound may include one or more of phytic acid (or salts thereof such as their potassium or sodium salts), sodium dibasic phosphate (Na2HPO4), sodium monobasic phosphate (NaH2PO4), and potassium monobasic phosphate (KH2PO4) salts.
- the phosphate compound is present in an amount effective to buffer the composition to a pH of from about 6.0 to a pH of about 8.0, or a pH of from about 6.5 to a pH of about 8.0, or a pH of from about 6.5 to a pH of about 7.5, or a pH of about 7.0 to a pH of about 7.5, or a pH of greater than 7.2 (or about 7.2) to a pH of 7.5 (or about 7.5) and can be present in the compositions at concentrations of from 0.3% (or about 0.3%) w/v to 0.9% (or about 0.9%) w/v, or from 0.4% (or about 0.4%) w/v to 0.85% (or about 0.85%) w/v, or from 0.5% (or about 0.5%) w/v to 0.8% (or about 0.8%) w/v or from 0.6% (or about 0.6%) w/v to 0.75% (or about 0.75%) w/v, based on
- the phosphate compound may be a combination of salts of the dibasic phosphate anion (HPO 4 ) 2- and salts of the monobasic phosphate anion (H 2 PO 4 )- where the concentration, prior to sterilization of the composition, of the dibasic phosphate anion (HPO4) 2- is from about 0.700% to about 0.900% and the concentration, prior to sterilization of the composition, the monobasic phosphate anion (H 2 PO 4 )- is from 0.500% to about 0.710%, by weight of the composition when present as the sodium salt mono- and heptahydrates, respectively.
- compositions of the present invention may also contain neutral salts (e.g., sodium chloride) to meet human physiologic osmolality requirements. It is well known that the presence of such neutral salts affects the pH of phosphate buffers. Increasing the concentration of neutral salts results in a negative shift in pH (i.e., resulting in more acidic environment). Without being limited by theory, it is believed that these departures from ideal behavior result from electrostatic interactions of the cations of the neutral and phosphate salts. This is illustrated in Figure 1 (reproduced from Robinson, H., W., The Influence of Neutral Salts on the pH of Phosphate Buffer Mixtures, J. Biol. Chem., LXXXII (3), 775-802, (1929)).
- neutral salts e.g., sodium chloride
- the neutral salt e.g., sodium chloride
- the neutral salt is present at a concentration of from 0.62% (or about 0.62%) to 0.66% (or about 0.66%), or from 0.58% (or about 0.58%) to 0.75% (or about 0.75%, or from 0.10% (or about 0.10%) to 0.28% (or about 0.28%), or from 0.00% to 0.35% (or about 0.35%), by weight, of the composition of the present invention.
- the compositions of the present invention 11 Docket No.
- VTN6124WOPCT1 comprise monobasic phosphate anions (H2PO4)- and dibasic phosphate anions (HPO4) 2- at following ratios: Neutral salt (e.g., sodium Monobasic phosphate anions (H 2 PO )-/ Dibasic 2- 4 chloride) Concentration (%) phosphate anions (HPO 4 ) Ratio 0.45% to 1.20% 0:1 to 0.45:1 0.50% to 0.90% 0.02:1 to 0.44:1 0.55% to 0.85% 0.10:1 to 0.34:1 0.60% to 0.80% 0.12:1 to 0.30:1 0.65% to 0.75% 0.14:1 to 0.24:1
- the compositions of the present invention optionally, comprise a reductant for quenching (or reducing) the chlorous acid compound so as to neutralize it from the composition.
- Suitable reductants include, but are not limited to, the following salts or (metal ions thereof): iron (II), bisulfite such as sodium metabisulfite, tin metal, formate, phosphite, hypophosphite, sulfur, thiosulfate (such as sodium thiosulfate), zinc metal, dithionite, manganese metal, aluminum metal, magnesium metal, dithiothreitol, NADH2, ascorbate, ferricyanide, hydroquinone, tyrosine, tyrosine copolymers, aldehydes (such as cinnamic aldehyde), N-acetylcysteine, butylated hydroxyanisole, butylated hydroxytoluene, ethylenediaminetetraacetic acid (EDTA), diethylenetriamine pentaacetic acid (DTPA) and ophthalmically compatible salts thereof, Cellobiose (a disaccharide with the
- the reductant may comprise from 15:85 or 10:90 polymethyl acryloyltyrosinate co N,N-dimethylacrylamide, L- 12 Docket No. VTN6124WOPCT1 glucose, 4-nitrophenol, vanillin, hydroquinone, ethylenediaminetetraacetic acid (EDTA), Cellobiose, PVP and mixtures thereof.
- the reductant may comprise 15:85 or 10:90 polymethyl acryloyltyrosinate co N,N-dimethylacrylamide, L-glucose, ethylenediaminetetraacetic acid (EDTA), Cellobiose, PVP and mixtures thereof.
- the reductant may comprise EDTA.
- the EDTA may be used in a molar excess compared to the chlorous acid compound.
- the EDTA may be used in concentrations of about 0.01 to about 0.075 wt% EDTA, or about 0.05 to about 0.075 wt% EDTA.
- the reductant and the chlorous acid compound are present such that the ratio, in molar equivalents, of the chlorous acid compound to the reductant is from 1:1 to 1:20, or 1:1 to 1:15, or 1:1 to 1:10, or 1:1 to 1:5, or greater than 1:1 to 1:1.5.
- the molar equivalents of chlorous acid compound to EDTA may be greater than 1.1 to 1.5, 1:2 to 1:5, or 1:3 to 1:5 or 1:4.
- the molar equivalents of chlorite to EDTA may be 1:2 to 1:5, or 1:3 to 1:5 or 1:4.
- the composition comprising the chlorous acid compound and reductant remains colorless or lightly colored, even after autoclaving, which can be determined visually or measured via known methods such as APHA color technique.
- the solution after autoclaving may have a APHA color value of less than about 180, or less than about 40.
- An Ophthalmologically Acceptable Carrier The compositions of the present invention comprise an ophthalmologically acceptable carrier.
- the ophthalmologically acceptable carrier may be water or an aqueous excipient solution.
- aqueous typically denotes a formulation wherein the excipient is at least about 50%, or at least about 75% or at least about 90% and up to about 95%, or about 99%, by weight, water.
- the compositions of the present invention are free of oils or oily substances (e.g., medium-chain triglycerides, castor oil, flaxseed oil and the like or mixtures thereof).
- substantially free as used with respect to the oil or lipid compounds, means the present compositions contain less than 0.05%, or less than 0.025%, or less than 0.01%, or 13 Docket No. VTN6124WOPCT1 less than 0.005%, of such oils or oily components, by weight, based on the total composition.
- the compositions are not multiphasic compositions such as oil in water emulsions.
- the water is preferably distilled water.
- the carrier is free of C1-4 alcohols such as methanol, ethanol, propanol, isopropanol, butanol, and the like which can sting, irritate, or otherwise cause discomfort to the eye.
- the water may be present in the ophthalmologically acceptable carrier at concentrations of from about 96% to about 99.9%, or from about 98% to about 99.5%, or from about 99.0% to about 99.5%, by weight of the total composition.
- the ophthalmologically acceptable carrier may be present at concentrations of from about 96% to about 99.5%, or from about 98% to about 99.5%, or from about 98.5% to about 99.2%, by weight of the total composition.
- the compositions may be sterile, namely such that the absence of microbial contaminants in the product prior to release or use are statistically demonstrated to the degree necessary for such products.
- the compositions may be selected to have no or substantially no detrimental, negative, harmful effect on the contact lens being therein or on the eye (or on the region around the eye).
- the compositions according to the present invention are physiologically compatible with the eye and ophthalmic devices.
- the composition should be “ophthalmologically safe” for use with an ophthalmic device such as a contact lens, meaning that a contact lens treated with the solution is generally suitable and safe for direct placement on or direct application to the eye without rinsing, that is, the solution is safe and comfortable for ophthalmic devices, of any frequency of application, wetted with the solution, including contact lenses of any wear frequency.
- An ophthalmologically safe composition has a tonicity and pH that is compatible with the eye and includes materials, and amounts thereof, that are ophthalmologically compatible and non-cytotoxic according to ISO standards and U.S. Food & Drug Administration (FDA) regulations.
- compositions of the present invention may be adjusted with tonicity agents, to approximate the osmotic pressure of normal lacrimal fluids, which is equivalent to a 0.9 percent 14 Docket No. VTN6124WOPCT1 solution of sodium chloride.
- the compositions may be made substantially isotonic with physiological saline used alone or in combination with other tonicity agents such as dextrose, otherwise if simply blended with sterile water and made hypotonic or made hypertonic the ophthalmic devices such as contact lenses may lose their desirable optical parameters.
- excess saline may result in the formation of a hypertonic composition, which will cause stinging, and eye irritation.
- the osmolality of the composition may be at least about 200 mOsm/kg to less than 500 mOsm/kg, or from about 200 to about 450 mOsm/kg, or from about 205 to about 380 mOsm/kg, or from about 210 to about 360 milliosmoles per kilogram (mOsm/kg), orfrom about 250 to about 350 mOsm/kg, or from about 270 to about 330 mOsm/kg, as measured using osmolality measurement method USP ⁇ 785> (current as of November, 2022).
- the ophthalmic compositions will generally be formulated as sterile aqueous compositions or as non-sterile compositions which are subsequently sterilized.
- suitable tonicity adjusting agents include (selected from or selected from the group consisting of), but are not limited to, sodium, potassium, calcium, zinc and magnesium chloride, alkali metal halides, dextrose, and the like and mixtures thereof. These agents may be used individually in amounts ranging from about 0.01 to about 2.5% w/v or from about 0.2 to about 1.5% w/v, based on the total composition.
- the tonicity adjusting agent may be sodium chloride which can be incorporated at concentrations of from about 0.4 to about 0.9% w/v, or from about 0.4 to about 0.7% w/v, or from about 0.5% to about 0.6% w/v.
- the ophthalmologically acceptable carrier can contain one or more of the above- mentioned tonicity agents.
- compositions of the present invention may have a pH of from about 6.0 to a pH of about 8.0, or a pH of from about 6.5 to a pH of about 8.0, or a pH of from about 6.5 to a pH of about 7.5, or a pH of about 7.0 to a pH of about 7.5, or a pH of about 7.2 to a pH of about 7.4.
- Compositions may have a pH matching the physiological pH of the human tissue to which the composition will contact or be directly applied.
- the pH of the ophthalmic composition may be adjusted using acids and bases, such as mineral acids, such as, but not limited to hydrochloric acid and bases such as sodium hydroxide. 15 Docket No.
- compositions of the present invention are also useful as packaging solutions for packaging of ophthalmic devices and for storing such ophthalmic devices.
- the packaging solutions of the present invention may have a viscosity of less than about 5.2 cP at 25oC.
- ophthalmic device refers to an object that resides in or on the eye. These devices can provide optical correction, cosmetic enhancement, light blocking (including UV, HEV, visible light and combinations thereof) glare reduction, therapeutic effect, including preventing the progression of myopia, wound healing, delivery of drugs or neutraceuticals, diagnostic evaluation or monitoring, or any combination thereof.
- Ophthalmic devices include (selected from or selected from the group consisting of), but are not limited to, soft contact lenses, intraocular lenses, overlay lenses, ocular inserts, punctual plugs, and optical inserts.
- the ophthalmic device may be a contact lens.
- Contact lenses (or “contacts”) are placed directly on the surface of the eyes (e.g., placed on the film of tears that covers the surface of the eyes).
- Contact lenses include soft contact lens (e.g., conventional or silicone hydrogel), rigid contact lenses or hybrid contact lenses (e.g., with soft skirt or shell).
- Soft contact lenses may be formed from hydrogels. Contact lenses useful with the compositions can be manufactured employing various conventional techniques, to yield a shaped article having the desired posterior and anterior lens surfaces.
- Contact lens polymer materials useful for manufacturing suitable contact lenses include (selected from or selected from the group consisting of), but are not limited to, acofilcon A, alofilcon A, alphafilcon A, amifilcon A, aquafilcon A, astifilcon A, atalafilcon A, balafilcon A, bisfilcon A, bufilcon A, comfilcon, crofilcon A, cyclofilcon A,balilcon A, deltafilcon A, delefilcon, deltafilcon B, dimefilcon A, drooxifilcon A, epsifilcon A, esterifilcon A, etafilcon A, fanfilcon A, focofilcon A, galyfilcon A, genfilcon A, govafilcon A, hefilcon A, hefilcon B, hefilcon D, hilafilcon A, hilafilcon B, hioxifilcon B, hioxifilcon C, hixoifilcon A, hydrofilcon A, lene
- the contact lenses may be manufactured using polymer materials selected from (or selected from the group consisting of) comfilcon, etafilcon A, galyfilcon A, senofilcon A, senofilcon C, nelfilcon A, hilafilcon, samfilcon, serafilcon, tetrafilcon A, vasurfilcon, vifilcon, and polymacon.
- Conventional hydrogel contact lenses do not contain silicone containing components, and generally have higher water content, lower oxygen permeability and moduli than silicone hydrogels.
- hydrogels are prepared from monomeric mixtures predominantly containing hydrophilic monomers, such as 2-hydroxyethyl methacrylate (“HEMA”), N-vinyl pyrrolidone (“NVP”) or polyvinyl alcohols.
- hydrophilic monomers such as 2-hydroxyethyl methacrylate (“HEMA”), N-vinyl pyrrolidone (“NVP”) or polyvinyl alcohols.
- HEMA 2-hydroxyethyl methacrylate
- NDP N-vinyl pyrrolidone
- United States Patents Nos.4,436,887, 4,495,313, 4,889,664, 5,006,622, 5,039,459, 5,236,969, 5,270,418, 5,298,533, 5,824,719, 6,420,453, 6,423,761, 6,767,979, 7,934,830, 8,138,290, and 8,389,597 disclose the formation of conventional hydrogels.
- Conventional hydrogels may be ionic or non-ionic and include (selected from or selected from the group consisting of) polymacon, etafilcon, genfilcon, hilafilcon, nesofilcon, nelfilcon, ocufilcon, omafilcon, lenefilcon and the like.
- the oxygen permeability of these conventional hydrogel materials is typically below 20-30 barrers.
- Silicon hydrogel formulations may include aquafilcon, balafilcon, samfilcon, lotrafilcon A and B, delefilcon, galyfilcon, senofilcon A, B and C, narafilcon, comfilcon, formofilcon, riofilcon, fanfilcon, stenfilcon, somofilcon, serafilcon, kalifilcon, verofilcon and the like.
- “Silicone hydrogels” refer to polymeric networks made from at least one hydrophilic component and at least one silicone-containing component.
- hydrophilic components examples include (meth)acrylates, styrenes, vinyl ethers, (meth)acrylamides, N-vinyl lactams, N-vinyl amides, N-vinyl imides, N- vinyl ureas, O-vinyl carbamates, O-vinyl carbonates, other hydrophilic vinyl compounds, and mixtures thereof.
- Non-limiting examples of hydrophilic components include N,N-dimethyl acrylamide (DMA), 2-hydroxyethyl methacrylate (HEMA), N-vinyl pyrrolidone (NVP), N-vinyl acetamide (NVA), N-vinyl-N-methylacetamide (VMA), and mixtures thereof.
- DMA N,N-dimethyl acrylamide
- HEMA 2-hydroxyethyl methacrylate
- NDP N-vinyl pyrrolidone
- NPA N-vinyl acetamide
- VMA N-vinyl-N-methylacetamide
- silicone-containing component may comprise at least one 17 Docket No.
- VTN6124WOPCT1 polymerizable group e.g., a (meth)acrylate, a styryl, a vinyl ether, a (meth)acrylamide, an N- vinyl lactam, an N-vinylamide, an O-vinylcarbamate, an O-vinylcarbonate, a vinyl group, or mixtures of the foregoing
- at least one siloxane group at least one siloxane group, and one or more linking groups (which may be a bond) connecting the polymerizable group(s) to the siloxane group(s).
- the silicone- containing components may, for instance, contain from 1 to 220 siloxane repeat units, from 3 to 100, from 3 to 40, or from 3 to 20 siloxane repeat units.
- the silicone-containing component may also contain at least one fluorine atom.
- the ophthalmic devices may also include a polymeric wetting agent, which may be incorporated into the ophthalmic device in a number of ways including, but not limited to, as a non-reactive polymer and become entrapped in the hydrogel upon polymerization forming a semi-interpenetrating network, may be polymerized (with or without crosslinking) in a preformed contact lens to form a fully or semi-interpenetrating network respectively or may be added to the packaging solution of the present invention and up-taken into the contact lens during sterilization Examples of these are disclosed in US6,367,929, US10,935,695, US8,053,539, US10,371,865, US10,370,476, US6,822,016, US7,431,152, US7,841,716 and US7,262,232.
- the polymeric wetting agent may be polymerizable, for example as polyamide macromers or prepolymers, and in this case, are covalently incorporated into the silicone hydrogels. Mixtures of polymerizable and non-polymerizable polyamides may also be used.
- suitable wetting agents include cyclic and linear polyamides, and specific examples include polyvinylpyrrolidone (PVP), polyvinylmethyacetamide (PVMA), polydimethylacrylamide (PDMA), polyvinylacetamide (PNVA), poly(hydroxyethyl(meth)acrylamide), polyacrylamide, and copolymers and mixtures thereof.
- the polymeric wetting agent may be PVP, a mixture of PVP (e.g., PVP K90) and PVMA (e.g., having a M w of about 570 KDa).
- PVP polyvinyl
- PVMA polyvinyl acrylate copolymer
- the polyamides When the polyamides are incorporated into the reactive monomer mixture they may have a weight average molecular weight of at least 100,000 daltons; greater than about 150,000; between about 150,000 to about 2,000,000 daltons; between about 300,000 to about 1,800,000 18 Docket No. VTN6124WOPCT1 daltons. Higher molecular weight polyamides may be used if they are compatible with the reactive monomer mixture.
- the hydrogel or silicone hydrogel formulations may also contain additional components such as, but not limited to, diluents, initiators, light absorbing compounds, including UV, HEV or visible light absorbers, photochromic compounds, pharmaceuticals, nutraceuticals, antimicrobial substances, tints, pigments, copolymerizable dyes, nonpolymerizable dyes, release agents, and combinations thereof.
- light absorbing compounds, photochromic compounds tints or dyes are preferably stable in the presence of the microbial growth inhibiting compound at the selected microbial growth inhibiting compound concentrations.
- An example of a UV absorber which is stable in the presence of chlorous acid compound is Norbloc.
- Silicone hydrogel lenses may contain a coating, and the coating may be the same or different material from the substrate.
- Silicone hydrogels may have moduli in the range of 60-200, 60-150 or 80 -130 psi, water contents in the range of 20 to 60% and contact angles less than about 100 ⁇ , less than about 80 ⁇ , and less than about 60 ⁇ .
- silicone hydrogels examples include acquafilcon, asmofilcon, balafilcon, comfilcon, delefilcon, enfilcon, fanfilcon, formofilcon, galyfilcon, lotrafilcon, lehfilcon, kalifilcon, narafilcon, riofilcon, samfilcon, senofilcon, serafilcon, somofilcon, stenfilcon, unifilcon, and verofilcon including all of their variants, as well as silicone hydrogels as prepared in US Patent Nos.4,659,782, 4,659,783, 5,244,981, 5,314,960, 5,331,067, 5,371,147, 5,998,498, 6,087,415, 5,760,100, 5,776,999, 5,789,461, 5,849,811, 5,965,631, 6,367,929, 6,822,016, 6,867,245, 6,943,203, 7,247,692, 7,249,848, 7,553,8
- the contact lens polymer material may be a silicone hydrogel polymer.
- the silicone hydrogel may be selected from (or selected from the group consisting of) acquafilcon, 19 Docket No. VTN6124WOPCT1 asmofilcon, balafilcon A, comfilcon, delefilcon, enfilcon, fanfilcon, galyfilcon, lotrafilcon, senofilcon, samfilcon, somofilcon, stenfilcon, riofilcon, lehfilcon, kalifilcon, serafilcon, unifilcon, verofilcon.
- compositions may also be useful for direct application to eye as a wetting or rewetting eye drop for providing relief to eye discomfort (e.g., burning sensations relating to the eye or general eye irritation).
- eye discomfort e.g., burning sensations relating to the eye or general eye irritation.
- the compositions of the present invention are not further mixed with another or separate composition(s) prior to direct application to the eye or for storing of (or as packaging solution for) ophthalmic devices (e.g., contacts) – namely the compositions of the present invention (or products thereof) are not in the form of 2- or multi- compositions or products.
- compositions described herein may, at the time of mixing, be free of or substantially free of boric acid, borates, non-chlorous acid preservatives (especially cationic preservatives), peroxides (e.g., hydrogen peroxide) or sources of peroxides, persulfates, glycerin, polyoxyethylene-castor oil and/or derivatives thereof.
- peroxides e.g., hydrogen peroxide
- sources of peroxides e.g., peroxide
- persulfates e.g., hydrogen peroxide
- glycerin e.g., polyoxyethylene-castor oil and/or derivatives thereof.
- borate refers to salts of boric acid and other pharmaceutically acceptable borates, or combinations thereof.
- Suitable borates include, but are not limited to, boric acid; pharmaceutically acceptable salts, such as alkaline metal salts such as sodium borate, potassium borate; alkaline earth metal salts such as calcium borate, magnesium borate; transition metal salts such as manganese borate; and mixtures thereof.
- pharmaceutically acceptable salts such as alkaline metal salts such as sodium borate, potassium borate; alkaline earth metal salts such as calcium borate, magnesium borate; transition metal salts such as manganese borate; and mixtures thereof.
- alkaline metal salts such as sodium borate, potassium borate
- alkaline earth metal salts such as calcium borate, magnesium borate
- transition metal salts such as manganese borate
- non-chlorous acid preservative means compounds, which are not chlorous acid compounds, but have antimicrobial properties. Examples of specific preservatives include, but are not limited to, 4-chlorocresol, 4-chloroxylenol, benzalkonium, benzalkonium chloride (BAK), benzoic acid, benzyl alcohol, chlorhexidine, chlorobutanol, imidurea, m-cresol, 20 Docket No.
- VTN6124WOPCT1 methylparaben, phenols 0.5%, phenoxyethanol, sorbate, propionic acid, propylparaben, sodium benzoate, sorbic acid, thimerosol, polyquaternium compounds (such as polyquarternium-42 and polyquarternium-1), biguanide compounds (e.g., polyhexamethylene biguanide or polyaminopropyl biguanide).
- Non-chlorous acid preservatives, especially cationic preservatives can be irritating to eye and/or cause allergic reactions, undesirably affecting consumers’ use of the eye care compositions or contact lens which contain (on its surface) such non-chlorous acid preservative due to the storage of the contact lens with such compounds.
- the term “sources of peroxides”, as used herein, means a compound or material that releases (or can release peroxide or hydrogen peroxide) in aqueous solution and includes, but are not limited to, barium peroxide, sodium peroxide, zinc peroxide, magnesium peroxide, calcium peroxide, strontium peroxide, lithium peroxide, butanone peroxide, cyclohexanone peroxide, benzoyl peroxide, urea hydrogen peroxide (carbamide peroxide, carbamide perhydrate, or percarbamide), percarbonates such as calcium percarbonate or magnesium percarbonate, tert-butylhydroperoxide, perborate salts such as sodium perborate, peroxy acids such as methyl ethyl ketone peroxide, mixtures thereof and derivatives.
- Peroxides e.g., hydrogen peroxide
- sources of peroxides can be harsh and irritating to eye and can 21 Docket No. VTN6124WOPCT1 undesirably affect consumers’ use of contact lens which contain (on its surface) the peroxides (e.g., hydrogen peroxide) and/or sources of peroxides due to the storage of the contact lens with such compounds.
- the term "persulfates”, as used herein, means persulfate anions or salts of such persulfates and other pharmaceutically acceptable persulfates, or combinations thereof.
- Suitable persulfates include, but are not limited to, sodium peroxymonosulfate, potassium peroxymonosulfate, sodium persulfate , ammonium persulfate potassium persulfate and mixtures thereof.
- Persulfates can be harsh and irritating to eye and can undesirably affect consumers’ use of contact lens which contain (on its surface) the persulfates due to the storage of the contact lens with such compounds.
- Humectants and/or demulcents such as carboxy vinyl polymers (e.g., carbomers), natural gums (e.g., guar gum, gum tragacanth), glycerin, polyoxyethylene-castor oil and/or derivatives thereof are well known thickening agents which, when present on surface of contact lenses, can undesirably affect consumers’ vision through contact lens, causing blurring or otherwise reducing vision clarity by either interacting with the surface of the contact lens or slowly diffusing from the tear fluid trapped between the eye-facing side of the contact lens and the corneal surface. Though the latter effect is generally temporary, dissipating within several minutes post insertion with trapped fluid being cleared by repetitive blinking, such visual impairing effects may be undesirable.
- carboxy vinyl polymers e.g., carbomers
- natural gums e.g., guar gum, gum tragacanth
- glycerin polyoxyethylene-castor oil and/or derivatives thereof
- substantially free as related to compounds selected from boric acid, borates, non-chlorous acid preservatives, peroxides (e.g., hydrogen peroxide) or sources of peroxides, persulfates, carboxy vinyl polymers (e.g., carbomers), natural gums (e.g., guar gum, gum tragacanth)glycerin, polyoxyethylene-castor oil and/or derivatives means that such compounds are present in the compositions of the present invention as impurities which are not intentionally added or are at a concentration of less than 2% (or about 2%), or less than 1.5% (or about 1.5%), or less than 1% (or about 1%), or less than 0.5% (or about 0.5%), or less than 0.1% (or about 0.1%), or less than 0.05% (or about 0.05%), or less than 0.01% (or about 0.01%), or less than 0.005% (or about 0.005%) by weight of the total composition.
- peroxides e.g., hydrogen
- compositions of the present invention may be free of such compounds. 22 Docket No. VTN6124WOPCT1
- contact lenses can be immersed in a composition of the present invention and stored in a suitable packaging container, in certain embodiments, a packaging container for single contact lens unit.
- a packaging container for the storage of a contact lens includes at least a sealing layer sealing the container containing an unused contact lens immersed in the composition of the present invention.
- the sealed container may be hermetically sealed packaging container and may have any form that creates a sealed space to contain the composition and contact lens.
- the hermetically sealed packaging container may have any suitable form include sealed packets formed from two sheets of plastic, metal or multilayer structures or a blister pack in which a base with a concave well containing a contact lens is covered by a metal, plastic or laminate sheet adapted for peeling in order to open the blister-pack.
- the sealed container may be formed from any suitable, generally inert packaging material providing a reasonable degree of protection to the lens.
- the packaging material may be formed of plastic material such as polypropylene, polysulfone (PSU), polyethersulfone (PESU), polycarbonate (PC), polyetherimide (PEI), polyamides, including nylons, polyolefins including polypropylene, polymethylpentene, (PMP), and olefin co-polymers, including COPs (Cyclic Olefin Polymer) and COCs,(Cyclic Olefin Co-polymers), acrylics, rubbers, urethanes, fluorocarbons, polyoxymethylene, polyvinylchloride (PVC), polyphenylsulfide (PPS), polycarbonate copolymers, polyvinylidene fluoride (PVDF), and the like and copolymers and blends of the foregoing.
- plastic material such as polypropylene, polysulfone (PSU), polyethersulfone (PESU), polycarbonate (PC), polyetherimide (PE
- Blends include polybutylene terephthalate polyester blends, including PBT and PC blends, PC/polyester blends, and polypropylene blended with COPs or COCs.
- the plastic material may be selected from polypropylene, COPs (Cyclic Olefin Polymer) and COCs, (Cyclic Olefin Co-polymers) and blends thereof.
- any water soluble, demulcent (or demulcent like – e.g., having demulcent properties such as viscosity increasing capabilities) polymer may also be employed in the composition of this invention provided that it has no (or no substantial) detrimental effect on the contact lens being stored or on the wearer of the contact lens (e.g., blurring or otherwise reducing vision clarity) at the concentrations used in the composition of the present invention or on the eye (or on the region around the eye).
- Particularly useful components are those, which are water soluble, for example, soluble at the concentrations used in the presently useful liquid aqueous media.
- Suitable water soluble demulcent polymers include, but are not limited to, demulcent polymers, such as block copolymer surfactants (e.g., 23 Docket No. VTN6124WOPCT1 block copolymers of polyethyleneoxide (PEO) and polypropyleneoxide (PPO)); polyvinyl alcohol, polyvinyl pyrrolidone; polyacrylic acid; polyethers such as polyethylene glycols (e.g., polyethylene glycol 300, polyethylene glycol 400) and polyethylene oxides; hyaluronic acid, and hyaluronic acid derivatives such as sodium hyaluronate) ; chitosan; polysorbates such as polysorbate 80, polysorbate 60 and polysorbate 40); dextrans such as dextran 70; cellulosic derivatives such as carboxy methyl cellulose methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, and methyl ethyl cellulose; acyclic polyamide
- the block copolymers of PEO and PPO include poloxamers and poloxamines, including those disclosed in US6,440,366, herein incorporated by reference in its entirety.
- the water-soluble demulcent polymer is selected from polyvinyl pyrrolidone, methyl ethyl cellulose, polyvinyl alcohol, polymethacrylic acid, carboxymethyl cellulose, propylene glycol, 1,3-propanediol, polyethylene glycols, and mixtures thereof.
- Water-soluble demulcent polymers may have molecular weights in excess of 100,000. When propylene glycol and/or 1,3-propanediol are used as water-soluble demulcent polymers, they may have molecular weights lower than 100,000.
- any water-soluble polymer when used in the packaging solutions of the present invention, it may be included and present in amounts up to about 0.5, 1 or 2 weight %, or between about 0.001 and about 2%, or between about 0.005 and about 1 weight %, or between about 0.01 and about 0.5 weight %, or between about 100 ppm by weight and about 0.5 weight %, all based upon the weight of total composition.
- any water soluble polymer when used in the direct application eye care formulation, such as an eye drop of the present invention, it may be included and present in amounts up to about 2, 5 or 10 weight %, or between about 0.001 and about 10 weight %, or between about 0.005 and about 2 weight % , or between about 0.01 and about 0.5 weight %, or between about 100 ppm by weight and about 2 weight%, all based upon the weight of total composition.
- the water-soluble demulcent polymer aids in preventing the ophthalmic device from sticking to the packaging container and may 24 Docket No.
- VTN6124WOPCT1 enhance the initial (and/or extended) comfort of the contact lens, packaged in the composition, when placed on the eye after removal from the packaging container.
- the demulcent polymer may be a cellulosic derivative.
- the cellulosic derivative may be present at concentrations of from about 0.002% to about 0.01%, or from about 0.004% to about 0.006%, by weight of the total composition of the present invention.
- Various other materials may be included with the compositions described herein. In the case of compositions of the present invention for direct application to the eye, surfactants may be included.
- Surfactants suitable for such use include, but are not limited to, ionic and nonionic surfactants (though nonionic surfactants are preferred), RLM 100, POE 20 cetylstearyl ethers such as Procol® CS20, poloxamer block copolymers (such as Pluronic® F68, and block copolymers such as poly(oxyethylene)-poly(oxybutylene) compounds set forth in US2008/0138310 (which publication is herein incorporated by reference).
- the poly(oxyethylene)-poly(oxybutylene) block copolymer may have the formula (EO) m (BO) n , wherein EO is oxyethylene and BO is oxybutylene, and wherein m is an integer having an average value of 10 to 1000 and n is an integer having an average value of 5 to 1000, as disclosed in US8,318,144; m may also be 10 and n may be 5.
- Surfactants may be present at concentrations of from about 0.01 to about 3%, or from about 0.01 to about 1%, or from about 0.02 to about 0.5%, or from about 0.02 to about 0.1%, by weight of the total composition of the present invention.
- the components may perform more than one function, for example, some demulcents may also function as surfactants (e.g., PEO-PPO and PEO-PBO block copolymers).
- one or more additional components may be, optionally, included in the composition. Such optional component(s) are chosen to impart or provide at least one beneficial or desired property to the composition.
- additional, but optional, components may be selected from components that are conventionally used in ophthalmic device care compositions.
- optional components include (or, are selected from or selected from the group consisting of) cleaning agents (for example in direct application eye drops or cleaning [or eye care solution]), wetting agents, nutrient agents, therapeutic agent, sequestering agents, viscosity builders, contact lens conditioning agents, antioxidants, and the like and mixtures thereof.
- cleaning agents for example in direct application eye drops or cleaning [or eye care solution]
- wetting agents for example in direct application eye drops or cleaning [or eye care solution]
- nutrient agents for example in direct application eye drops or cleaning [or eye care solution]
- wetting agents for example in direct application eye drops or cleaning [or eye care solution]
- nutrient agents for example in direct application eye drops or cleaning [or eye care solution]
- wetting agents for example in direct application eye drops or cleaning [or eye care solution]
- nutrient agents for example in direct application eye drops or cleaning [or eye care solution]
- wetting agents for example in direct application eye drops or cleaning [or eye care solution]
- nutrient agents for example in direct application eye drops or cleaning
- the ophthalmic solution comprises about 0.01 to about 0.02 wt% sodium chlorite, a phosphate buffer, about 0.01 to about 0.075 wt% EDTA, or about 0.05 to about 0.075 wt% EDTA, about 0.005 to about 0.01 wt% methyl ethyl cellulose and optionally up to about 1, about 1.5 or about 2 wt% PVP K30, K60 or K90, K60 preferred), all based on the ophthalmic solution as formulated, prior to autoclaving.
- the ranges may be combined in any permutation.
- the ophthalmic solution may be used as a packaging solution with contact lenses, including silicone hydrogel contact lenses, comprising PVP.
- All components in the ophthalmic solution of the present invention should be water- soluble.
- One or more therapeutic agent may also be incorporated into the ophthalmic solution.
- a wide variety of therapeutic agents may be used, so long as the selected active agent is inert in the presence of chlorous acid compounds (e.g., chlorites) or oxidating agents generally.
- Suitable therapeutic agents include those that treat or target any part of the ocular environment, including the anterior and posterior sections of the eye and include pharmaceutical agents, vitamins, nutraceuticals combinations thereof and the like.
- Suitable classes of active agents include antihistamines, antibiotics, glaucoma medication, carbonic anhydrase inhibitors, anti-viral agents, anti-inflammatory agents, non-steroid anti-inflammatory drugs, antifungal drugs, anesthetic agents, miotics, mydriatics, immunosuppressive agents, antiparasitic drugs, anti- protozoal drugs, combinations thereof and the like.
- active agents When active agents are included, they are included in an amount sufficient to produce the desired therapeutic result (a “therapeutically effective amount”).
- Useful optional sequestering agents include, but are not limited to, citric acid, sodium citrate and the like and mixtures thereof. 26 Docket No.
- the method of packaging and storing a contact lens comprises immersing the device in the compositions described above in a suitable container.
- the method may include immersing the device in the composition prior to delivery to the customer/wearer, directly following manufacture of the contact lens.
- the incorporation and storing of the device in the compositions may occur at an intermediate point before delivery to the ultimate customer (wearer) but following manufacture and transportation of the device in a dry state, wherein the dry device is hydrated by immersing the device in the compositions.
- a package for delivery to a customer may comprise a hermetically sealed container containing one or more unused devices (e.g., contact lenses) immersed in the compositions.
- the steps for packaging the ophthalmic device in the composition of the present invention may include: (1) molding an ophthalmic device (e.g., contact lens) in a mold comprising at least a first and second mold portion, (2) removing the device from the mold portions and removal of unreacted monomer and processing agents, (3) introducing the composition and the device into the packaging (or container), and (4) sealing the packaging.
- the method may also include the step of sterilizing the contents of the packaging.
- Sterilization may take place prior to, or most conveniently after, sealing of the container and may be performed by any suitable method known in the art, e.g., by autoclaving of the sealed container at temperatures of about 120° C. or higher (autoclave or steam sterilization method), or by using ultraviolet (UV) sterilization or gamma electron beam sterilization methods.
- the compositions of the present invention are sterilized by autoclave sterilization.
- the packaging may be a plastic blister packaging (or package), including a recess for receiving an ophthalmic device and the composition, where the recess is hermetically sealed with lidstock prior to sterilization.
- VTN6124WOPCT1 The following examples are provided to enable one skilled in the art to practice the compositions and are merely illustrative of the invention. The examples should not be read as limiting the scope of the invention as defined in the claims. 28 Docket No. VTN6124WOPCT1 EXAMPLES The compositions of the present invention as described in following examples illustrate specific embodiments of compositions of the present invention but are not intended to be limiting thereof. Other modifications can be undertaken by the skilled artisan without departing from the spirit and scope of this invention. Materials used in the following Examples are provided as listed below: Material Supplier Sodium chloride J. T.
- Table 1 shows the formulation for a composition useful as a solution for storing (or as packaging) solution for ophthalmic devices (e.g., contact lenses) or direct application eye drop solution, which composition can be prepared using conventional mixing technology.
- EDTA Disodium ethylene diamine tetraacetic acid
- Table 1 shows the formulation for a composition useful as a solution for storing (or as packaging) solution for ophthalmic devices (e.g., contact lenses) or direct application eye drop solution, which composition can be prepared using conventional mixing technology.
- Table 1 Component Weight % (the balance is water) Sodium Chloride 0.85% Monobasic sodium p hosphate*H2O 0.10% 29 Docket No. VTN6124WOPCT1 Dibasic sodium phosphate*7H 2 O 0.63% Sodium Chlorite (anhydrous)* 0.013% EDTA 0.01% Methyl ethyl cellulose (MEC) 0.005% Composition Properties pH range 7.1 - 7.3 Osmolality range (mOsm/kg) 300 – 330 * Provided as stabilized sodium chlorite 80% with 20% sodium chloride.
- Nominal chlorite content in the composition of Table 1 was about 78 ⁇ g/mL
- the composition of Table 1 was prepared and filter sterilized through a 0.22 ⁇ m membrane using a 150-mL Analytical Filter Unit. The filtered composition was then aseptically transferred into new individual sterile specimen cups for storage and testing.
- the TSA and SDA plates were incubated at 30-35oC and 20-25oC respectively, for 2-7 days.
- Sterile filtered deionized (DI) water and inoculating loops were used to resuspend the designated test microorganisms from the plate surfaces and the suspensions were aseptically transferred with a sterile pipette into individual 50mL centrifuge tubes.
- 30 Docket No. VTN6124WOPCT1 The Aspergillus brasiliensis (AB) and Fusarium keratoplasticum (FK) spore suspensions were prepared in the same manner. The FK spore suspension was harvested from the plates following the full 7 days of plate incubation at 20-25oC.
- test microorganism suspensions were diluted until their population counts could be estimated using a hemocytometer. A population count of approximately 1.0 x 107 cells/mL was targeted for each final test microorganism suspension. Depending on the test microorganism targeted suspension count, an aliquot ranging from 2.5 ⁇ L to 100 ⁇ L) was inoculated into 20mL of the composition of Table 1 to obtain an average starting microorganism population count of approximately 7000 CFU/mL. Each inoculated sample of the composition of Table 1 containing the designated test microorganism was stored at room temperature and at Day 0, Day 1, Day 2, and Day 3 samples were pour-plated in duplicate (Day 0 only) or triplicate with either molten TSA or SDA containing chloramphenicol as required.
- brasiliensis were similar for the TSA and SDA+chloramphenicol. 31 Docket No. VTN6124WOPCT1 Consequently, TSA enabled the enumeration of A. brasiliensis on plates without interference due to sporulation.
- SDA + chloramphenicol was found to inhibit growth so spread plating onto prepared SDA plates without chloramphenicol was performed.
- the TSA plates and SDA were incubated at 30-35oC and 20-25oC respectively, for 2-7 days to quantitate the designated test microorganism population counts following room temperature (i.e., 25oC) incubation in the composition of Table 1.
- Figure 1 also shows bacteriostatic/fungistatic response for mold spores (AB and FK) and the gram-positive BS vegetative cells due to incubation in composition of Table 1.
- Example 2 The composition of Table 2 shows the formulation for a composition useful as a solution for storing (or as packaging) solution for ophthalmic devices (e.g., contact lenses) or direct application eye drop solution, which composition can be prepared using conventional mixing technology.
- ophthalmic devices e.g., contact lenses
- direct application eye drop solution which composition can be prepared using conventional mixing technology.
- VTN6124WOPCT1 Table 2 Component Weight % (the balance is water) Sodium Chloride 0.830% Monobasic sodium 0.100% phosphate*H 2 O Dibasic sodium phosphate*7H 2 O 0.630% Disodium EDTA 0.010% Sodium chlorite (anhydrous)*** 0.0125% Methyl ethyl cellulose (MEC) 0.005% *** Provided as stabilized sodium chlorite 80% with 20% sodium chloride. Nominal chlorite content in the composition of Table 2 was about 75 ⁇ g/mL One liter of the composition of Table 2 was prepared.
- the one-liter sample was, then, divided into two equal portions - the first portion was sterile filtered through a 0.22 ⁇ m membrane using a 150-mL Analytical Filter Unit and the other (second) portion was utilized as the base control sample. These portions were held at room temperature (i.e., about 25oC) for the duration of the testing described below.
- Each vial of microorganism pellets were removed from refrigerated storage and allowed to equilibrate to room temperature (about 30 minutes). 33 Docket No. VTN6124WOPCT1 2. Prior to use, hydration and dilution fluids provided by manufacturer were warmed to 34°C–38°C. Sterile pH 7.2 phosphate buffer is recommended for hydration of the lyophilized preparation. 3. Microorganism pellet(s) were transferred, using sterile forceps, to the hydration fluid and serially diluted to a target of target 100 CFU/mL. 4. The prepared microorganism suspension was placed into a 34°C–38°C incubator for 30 minutes to assure complete hydration. 5.
- Example 8 Pot Life Experiments (L-glucose) The pot life of the experimental packaging solution with 0.01% chlorite was evaluated by adding 5 equivalents of L-glucose and analyzing the resultant solutions for chlorite content as a function of time for approximately 24 hours at room temperature. Controls with no reductant and blank solutions were included in the sample queue to facilitate spacing of the injections over time.
- the pot life samples were prepared as follows. About 10 mL of the composition of experimental packaging solution was placed into several 20 mL glass screw cap scintillations vials. The vials of step 1 were sealed with gray butylene caps and stored at room temperature in 35 Docket No.
- VTN6124WOPCT1 a light blocking container and placed in refrigerator at as function of time (typically 1 vial every day for 5 days). Samples were analyzed for chlorite concentration at each day for 5 days via ion chromatography with conductivity detection. The separation was performed using a Dionex AS9-HC column, 4 mm diameter X 250 mm length with a matching guard column. The mobile phase was 9 mmol.L sodium bicarbonate and the suppressor eluent was 500 mL sulfuric acid. The injection volume and flow rate parameters were generally set at 20 ⁇ L and 1 mL/min, respectively. Standardization was performed using certified chlorite reference standards diluted to the applicable concentration regime, typically 0.1 – 20 ⁇ g/mL.
- the chlorite peak area of standard solutions was fitted to a least-squares fit with the corresponding chlorite concentrations.
- the equation of the least-squares regression was used to calculate the chlorite concentration of test solutions. No meaningful decrease in chlorite content was observed for the control and L-glucose solutions, indicating sufficient chlorite concentration remains through the packaging process to sterilization. Examples 9-13 Examples 3-7 were repeated using tyrosine as the reductant. Substantial discoloration (yellow to amber) of the packaging solution was observed even when tyrosine was present in a sub-stoichiometric amount.
- VTN6124WOPCT1 13 3.85 Amber 0.00051 10.9 a Molar equivalents of tyrosine relative to chlorite anion.
- Examples 14-18 of para-substituted benzaldehydes and vanillin were evaluated as potential reductants. The para-substituents were selected to maximize the range of inductive effect from the highly electron-withdrawing chloro substituent to the highly electron-donating methoxy substituent. Vanillin was also selected as it is a naturally occurring aldehyde.
- vanillin contains a phenol moiety para to the aldehyde functional group, as shown below:
- a phosphate-buffered saline solution containing 0.01% sodium chlorite was spiked with approximately 8 equivalents of each of the benzaldehydes.
- Half of the samples were immediately autoclaved and then all solutions were incubated at room temperature for two weeks. At the two-week mark, the samples were frozen to stop further reaction and submitted for chlorite analysis. The samples were thawed and mixed thoroughly prior to analysis by ion chromatography using the method described above. Table 5 provides a summary of the results.
- vanillin which exhibited a mild vanilla scent in dilute solution
- the model benzaldehydes displayed an intense odor unacceptable for packaged contact lenses.
- the solutions of the para-substituted benzaldehydes remained clear and colorless.
- the vanillin solution assumed a faint rose color immediately upon autoclave, consistent with oxidation to produce a more highly conjugated ⁇ system. Incubation at room temperature alone produced no color.
- VTN6124WOPCT1 Table 6 Component Weight, g Weight % NaCl 8.32 0.84 Monobasic sodium phosphate, monohydrate 1.03 0.64 Dibasic sodium phosphate, heptahydrate 6.31 0.10 Disodium EDTA 0.0968 0.0098 Methyl ether cellulose 0.0498 0.0050 Sodium chlorite 0.1058 0.107 Water 976.22 N/A Glutathione and methionine represent the thiol functionality and exhibited an objectionable odor even in dilute solution. All four of these reductants were soluble in the packaging solution and produced a solution that was clear with no hint of color. Upon autoclave, the cellobiose reacted with chlorite to produce a faint rose color.
- Table 8 shows the formulations for compositions having a range of chlorite concentrations useful as a solution for storing (or as packaging) solution for ophthalmic devices (e.g., contact lenses) or direct application eye drop solution, which composition was prepared using conventional mixing technology.
- samples of each of the compositions of Examples 23-27 were poured from the original specimen cup containers and filter sterilized through a 0.22 ⁇ m membrane using a 150-mL Analytical Filter Unit. The filtered individual compositions were then aseptically transferred into new individual sterile specimen cups for storage and testing.
- microorganisms were used to assess microbial activity: ⁇ ⁇ (AB) Aspergillus brasiliensis ((Quanti-CultTM)) - ATCC 16404 (Remel Inc.) ⁇ ⁇ (BS) Bacillus subtilis – subspecies spizizenil (Epower TM) - ATCC 6633 (Microbiologics®) ⁇ ⁇ (CA) Candida albicans (Epower TM) - ATCC 10231 (Microbiologics ® ) 40 Docket No.
- VTN6124WOPCT1 The test microorganisms were resuspended following manufacturers’ instructions and approximately 0.5mL aliquots were spread plated onto two separate tryptic soy agar (TSA) media and Sabouraud dextrose agar (SDA) plates. The TSA and SDA plates were incubated at 30-35oC and 20-25oC respectively, for 2-7 days. Sterile filtered deionized (DI) water and inoculating loops were used to resuspend the designated test microorganisms from the plate surfaces and the suspensions were aseptically transferred with a sterile pipette into individual 50mL centrifuge tubes.
- DI Sterile filtered deionized
- test microorganism suspensions were diluted until their population counts could be estimated using a hemocytometer. A population count of approximately 1.0 x 10 7 cells/mL was targeted for each final test microorganism suspension. Depending on the test microorganism targeted suspension count, an aliquot ranging from 2.5 ⁇ L to 100 ⁇ L) was inoculated into 20mL of each of the samples of the test compositions of Table 3 to obtain an average starting microorganism population count of approximately 7000 CFU/mL.
- Each inoculated sample of the compositions of Table 8 containing the designated test microorganism was stored at room temperature and at Day 0, Day 1, Day 2, and Day 3 samples were pour-plated in duplicate (Day 0 only) or triplicate with either molten TSA or SDA containing chloramphenicol as required. The aliquot volumes were bracketed to increase the chances of the pour plate count results to be within the 25 CFU – 300 CFU countable range. All pour plate sample volumes were adjusted to 1mL using sterile water for injection (WFI) (i.e., 50 ⁇ L + 950 ⁇ L WFI) to allow for sufficient sample dispersion. AB was pour-plated with both TSA and SDA + chloramphenicol. When pour plated in parallel, the counts of A.
- WFI sterile water for injection
- brasiliensis were similar for the TSA and SDA+chloramphenicol. Consequently, TSA enabled the enumeration of A. brasiliensis on plates without interference due to sporulation.
- the results are shown for Aspergillus brasiliensis and the bacteria Bacillus subtilis – subspecies spizizenii. Log counts for Candida Albicans are shown in Table 9, below. 41 Docket No. VTN6124WOPCT1 Table 9 C.
- the microorganism growth was less than a 0.2 log, or no increase in the count throughout the test period, including after 2, 8, 13 and 22 days from spiking for the yeast Candida albicans, the fungus Aspergillus brasiliensis and the bacteria Bacillus subtilis – subspecies spizizenii, respectively.
- Candida albicans and the bacteria Bacillus subtilis – subspecies spizizenii decreased over the test period for all chlorite concentrations evaluated, when each microorganism was spiked into the composition of Table 8 containing at least 0.84 ⁇ g/ml of chlorite.
- the fungus Aspergillus brasiliensis count remained the same (within test limits) at the lowest chlorite concentrations (0.84 and 1.7 ⁇ g/ml) and decreased over the test period at the higher concentrations (about 0.2 to about 0.5 log reduction at 3.7 and 7.6 ⁇ g/ml and 2.5 log reduction at 15 ⁇ g/ml.
- Examples 23-27 show that a range of chlorite concentration provide effective inhibition of the growth of microorganisms across at least 22 days.
- Examples 23-27 also show that elevated concentration of EDTA, approximately 0.075%, reduces microbial growth in a single autoclave and PVP ensures that the advancing contact angle is not adversely impacted, particularly when used in conjunction with chlorite.
- the reaction mixture was then irradiated using 420 nm LED lights having an intensity of about 3.5 mW/cm 2 for 8 hours.
- the reaction mixture was quenched in air and cooled to room temperature.
- the solvent was removed under reduced pressure, and the crude product was dissolved in dichloromethane and precipitated in n-hexanes to afford a white solid.
- the precipitation process was repeated thrice in n-hexanes and once in cold diethyl ether.
- the white solid was dried in vacuum oven at 60 o C overnight (80% yield).
- the monomer ratio of the tyrosine acrylamide (TAA) and N,N-dimethylacrylamide (DMA) copolymer may be varied to fine-tune the aqueous solubility and reduction capacity of the copolymer. It is further possible that by adjusting the ratio of TAA to DMA, that additional benefits, such as lens lubricity, may be obtained by promoting weak sorption of the copolymer to the lens surface. It will be appreciated that the embodiments illustrated and described herein are among myriad embodiments within the scope of the invention as set forth in the appended claims.
- a sealed ophthalmologic product or kit comprising: a) a composition for storing contact lenses as an admixture or mixture: i. a chlorous acid compound in an amount effective to inhibit the growth of microorganisms in the composition; ii. a phosphate compound; iii.
- a reductant for neutralizing the chlorous acid compound optionally, a reductant for neutralizing the chlorous acid compound, provided that, after the reductant’s admixture to the composition, the chlorous acid compound remains effective to inhibit the growth of microorganisms in the composition for a period of time; and iv. an ophthalmologically acceptable carrier comprising one or more tonicity agents at least one contact lens sealed in a container with the composition and b) a container comprising a sealed compartment comprising at least one contact lens in the presence of the composition.
- the phosphate compound is a combination of salts of the dibasic phosphate anion (HPO4) 2- and salts of the monobasic phosphate anion (H 2 PO 4 )-. 7.
- the phosphate compound is sodium dibasic phosphate (Na2HPO4), sodium monobasic phosphate (NaH2PO4) or a mixture thereof.
- the phosphate compound buffer is present in the composition at concentrations of from about 0.3% w/v to about 0.9% w/v, from about 0.4% w/v to about 0.85% w/v, from about 0.5% w/v to about 0.8% w/v or from about 0.6% w/v to about 0.75% w/v based on the total composition upon formulation.
- the composition further comprises a reductant.
- reductant is selected from iron (II), bisulfite, tin metal, formate, phosphite, hypophosphite, sulfur, thiosulfate, zinc metal, dithionite, manganese metal, aluminum metal, magnesium metal, dithionite, manganese metal, aluminum metal, magnesium metal, dithiothreitol, NADH2, ascorbate, ferricyanide, hydroquinone, tyrosine, aldehydes, N-acetylcysteine, butylated hydroxyanisole, butylated hydroxytoluene, ethylenediaminetetraacetic acid (EDTA), diethylenetriamine pentaacetic acid (DTPA) and ophthalmically compatible salts thereof, Cellobiose, glucose (L and D isomers), phenols, Docket No.
- VTN6124WOPCT1 polymeric aldehydes, poly methyl acryloyltyrosinate co N,N-dimethylacrylamide, poly Norbloc (2-(2H-benzo[d][1,2,3]triazol-2-yl)-4-(2-hydroxyethyl)phenol) co N,N-dimethylacrylamide, polymeric phenols or mixtures thereof.
- the reductant is selected from ethylenediaminetetraacetic acid (EDTA), Cellobiose, glucose (L and D isomers), phenols, or mixtures thereof.
- the composition further comprises a demulcent polymer.
- the demulcent polymer is selected from block copolymer surfactants; polyvinyl alcohol, polyvinyl pyrrolidone; polyacrylic acid; polyethers; hyaluronic acid and hyaluronic acid derivatives; chitosan; polysorbates; dextrans; cellulosic derivatives; acyclic polyamides and mixtures thereof. 15.
- the demulcent polymer is selected from polyvinyl pyrrolidone, methyl ethyl cellulose, polyvinyl alcohol, polymethacrylic acid, carboxymethyl cellulose, propylene glycol, 1,3-propanediol, polyethylene glycols, and mixtures thereof. 16.
- the demulcent polymer is a cellulosic derivative present at concentrations of from about 0.002% to about 0.01%, or from about 0.004% to about 0.006%, by weight of the total composition. 18.
- the demulcent polymer is a water-soluble polymer present in amounts up to about 0.5, about 1 or about 2 weight %, or between about 0.001 and about 2%, between about 0.005 and about 1 weight %, between about 0.01 and about 0.5 weight %, or between about 100 ppm by weight and about 0.5 weight %, all based upon the weight of total composition. 19.
- the composition has an osmolality is from about 200 mOsm/kg to less than about 500 mOsm/kg, from about 200 to about 450 mOsm/kg, from about 205 to about 380 mOsm/kg, from about 210 to about 360 (mOsm/kg), from about 250 to about 350 mOsm/kg, from about 270 to about 330 mOsm/kg, or about 205 mOsm/kg to about 350 mOsm/kg.
- composition is free of or substantially free of one or more of boric acid, borates, non-chlorous acid preservatives, peroxides or sources of peroxides, persulfates, carboxy vinyl polymers, natural gums, glycerin, polyoxyethylene-castor oil and derivatives thereof.
- composition is free of boric acid, borates, non-chlorous acid preservatives, peroxides or sources of peroxides, persulfates, carboxy vinyl polymers, natural gums, glycerin, polyoxyethylene-castor oil and derivatives thereof.
- a method of inhibiting the growth of microorganisms in a composition for a period of time occurring from preparation of the composition to sterilization of the composition in sealed a container comprising the steps of: a. mixing a composition comprising: iv. a chlorous acid compound in an amount effective to inhibit the growth of microorganisms in the composition; v. a phosphate compound; and vi. optionally, a reductant for neutralizing the chlorous acid compound after admixture to the composition ; b. storing the composition for the period of time during which time there is an inhibition of growth of microorganisms; c. placing the composition in a container; d. sealing the container of step c.; e.
- the container further comprises an ophthalmic device.
- the ophthalmic device is a contact lens.
- the contact lens is a conventional hydrogel contact lens or a silicone hydrogel contact lens. 35.
- the contact lens further comprises a water-soluble polymer entrapped therein.
- the contact lens is from polymeric material selected from conventional hydrogel polymers or silicon hydrogel polymers.
- the period of time is at least 1 day.
- a method of packaging and sterilizing a composition in sealed a container comprising the steps of: a. mixing a composition comprising: i. a chlorous acid compound in an amount effective to inhibit the growth of microorganisms in the composition; ii. a phosphate compound; and iii. optionally, a reductant for neutralizing the chlorous acid compound after admixture to the composition; Docket No. VTN6124WOPCT1 b. placing the composition in a container; c. sealing the container of step b.; d. sterilizing the container of the c.
- the composition is free of or substantially free of one or more of boric acid, borates, non-chlorous acid preservatives, peroxides (e.g., hydrogen peroxide) or sources of peroxides, persulfates, carboxy vinyl polymers, natural gums, glycerin, polyoxyethylene-castor oil and derivatives thereof.
- peroxides e.g., hydrogen peroxide
- sources of peroxides, persulfates carboxy vinyl polymers, natural gums, glycerin, polyoxyethylene-castor oil and derivatives thereof.
- the contact lens is from polymeric material selected from conventional hydrogel polymers or silicone hydrogel polymers. 47. The method of any of the preceding method embodiments and any succeeding method embodiments, wherein the composition is manufactured under sterile conditions or sterilized during and/or after the period of time. 48. The method of any of the preceding method embodiments, wherein the composition is sterilized after the period of time by a sterilization process selected from autoclave sterilization, UV sterilization and gamma electron beam sterilization. 49.
- the chlorous acid compound is present at a concentration of from about 0.002% to about 0.200%, from about 0.0020% to about 0.1000%, Docket No. VTN6124WOPCT1 or from about 0.0050% to about 0.1000%, or from about 0.0075% to about 0.1000%, or from about 0.0080% to about 0.0500%, or from about 0.0090% to about 0.0200%, or from about 0.0095% to about 0.0150%, or about 0.01% of the composition upon formulation. 50.
- the chlorous acid compound is selected from water soluble alkali metal chlorites, water soluble alkaline metal chlorites and mixtures thereof.
- the chlorite is selected from potassium chlorite, sodium chlorite, calcium chlorite, magnesium chlorite and mixtures thereof.
- the chlorite comprises sodium chlorite.
- the phosphate compound is a combination of salts of the dibasic phosphate anion (HPO4) 2- and salts of the monobasic phosphate anion (H 2 PO 4 )-.
- HPO4 dibasic phosphate anion
- H 2 PO 4 monobasic phosphate anion
- the phosphate compound buffer is present in the composition at concentrations of from about 0.3% w/v to about 0.9% w/v, from about 0.4% w/v to about 0.85% w/v, from about 0.5% w/v to about 0.8% w/v or from about 0.6% w/v to about 0.75% w/v based on the total composition upon formulation.
- the composition further comprises a reductant.
- VTN6124WOPCT1 The method of any of the preceding embodiments and any succeeding embodiments, wherein the reductant is selected from iron (II), bisulfite, tin metal, formate, phosphite, hypophosphite, sulfur, thiosulfate, zinc metal, dithionite, manganese metal, aluminum metal, magnesium metal, dithionite, manganese metal, aluminum metal, magnesium metal, dithiothreitol, NADH2, ascorbate, ferricyanide, hydroquinone, tyrosine, aldehydes, N-acetylcysteine, butylated hydroxyanisole, butylated hydroxytoluene, ethylenediaminetetraacetic acid (EDTA), diethylenetriamine pentaacetic acid (DTPA) and ophthalmically compatible salts thereof, Cellobiose, glucose (L and D isomers), phenols, polymeric aldehydes, poly methyl acrylo
- the reductant is selected from ethylenediaminetetraacetic acid (EDTA), Cellobiose, glucose (L and D isomers), phenols, or mixtures thereof.
- EDTA ethylenediaminetetraacetic acid
- the reductant when present, is present such that the ratio, in molar equivalents, of the chlorous acid compound to the reductant is from 1:1 to 1:20, or1:1 to 1:15, or 1:1 to 1:10, or 1:1 to 1:5, or greater than 1:1 to 1:1.5 of the composition prior to sterilization.
- the composition further comprises a demulcent polymer.
- the demulcent polymer is selected from block copolymer surfactants; polyvinyl alcohol, polyvinyl pyrrolidone; polyacrylic acid; polyethers; hyaluronic acid and hyaluronic acid derivatives; chitosan; polysorbates; dextrans; cellulosic derivatives; acyclic polyamides and mixtures thereof. Docket No.
- VTN6124WOPCT1 The method of any of the preceding embodiments and any succeeding embodiments, wherein the demulcent polymer is selected from polyvinyl pyrrolidone, methyl ethyl cellulose, polyvinyl alcohol, polymethacrylic acid, carboxymethyl cellulose, propylene glycol, 1,3-propanediol, polyethylene glycols, and mixtures thereof.
- the demulcent polymer is methyl ethyl cellulose.
- the demulcent polymer is a cellulosic derivative present at concentrations of from about 0.002% to about 0.01%, or from about 0.004% to about 0.006%, by weight of the total composition.
- any of the preceding embodiments and any succeeding embodiments wherein the chlorous acid compound remains effective to inhibit the growth of microorganisms in the composition for at least seven days. 70.
- the method of any of the preceding embodiments and any succeeding embodiments, wherein the composition has an osmolality is from about 200 mOsm/kg to less than about 500 mOsm/kg, from about 200 to about 450 mOsm/kg, from about 205 to about 380 mOsm/kg, from about 210 to about 360 (mOsm/kg), from about 250 to about 350 mOsm/kg, from about 270 to about 330 mOsm/kg, or about 205 mOsm/kg to about 350 mOsm/kg.
- composition is package or sterilized during and/or after the period of time.
- composition is sterilized after the period of time by a sterilization process selected from autoclave sterilization, UV sterilization and gamma electron beam sterilization.
- a sterilization process selected from autoclave sterilization, UV sterilization and gamma electron beam sterilization.
- the composition is free of or substantially free of one or more of boric acid, borates, non-chlorous acid preservatives, peroxides or sources Docket No.
- the container is a plastic blister package, including a recess for receiving an ophthalmic device and the composition, where the recess is hermetically sealed with lidstock prior to sterilization.
- the reductant comprises EDTA
- the chlorous acid compound comprises at least one chlorite compound and the chlorite compound and EDTA are present in molar equivalents of 1:2 to 1:5, or 1:3 to 1:5 or 1:4 upon formulation of the composition.
- the reductant comprises EDTA in a concentration of about 0.01 to about 0.075 wt% based upon the total composition upon formulation.
- the antimicrobial inhibiting compound concentration is reduced after autoclaving by at least about 50%, about 70%, about 80% or about 90%.
- hydrogel contact lens is silicone hydrogel contact lens.
- Docket No. VTN6124WOPCT1 The product or kit of any of the preceding embodiments and any succeeding embodiments wherein the contact lens is a hybrid contact lens.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Inorganic Chemistry (AREA)
- Dentistry (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne des compositions contenant un composé d'acide chloreux et un composé de phosphate, en particulier des compositions de soins oculaires, permettant d'obtenir un pH et une tonicité physiologiquement compatibles ainsi que de bonnes propriétés bactériostatiques. L'invention concerne également des procédés d'utilisation des compositions de la présente invention.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263476537P | 2022-12-21 | 2022-12-21 | |
US202263476553P | 2022-12-21 | 2022-12-21 | |
US63/476,537 | 2022-12-21 | ||
US63/476,553 | 2022-12-21 | ||
US202363492288P | 2023-03-27 | 2023-03-27 | |
US63/492,288 | 2023-03-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024134381A1 true WO2024134381A1 (fr) | 2024-06-27 |
Family
ID=89321480
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2023/062628 WO2024134381A1 (fr) | 2022-12-21 | 2023-12-13 | Compositions pour dispositifs ophtalmologiques |
PCT/IB2023/062625 WO2024134380A1 (fr) | 2022-12-21 | 2023-12-13 | Compositions pour dispositifs ophtalmologiques |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2023/062625 WO2024134380A1 (fr) | 2022-12-21 | 2023-12-13 | Compositions pour dispositifs ophtalmologiques |
Country Status (1)
Country | Link |
---|---|
WO (2) | WO2024134381A1 (fr) |
Citations (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3408429A (en) | 1963-09-11 | 1968-10-29 | Ceskoslovenska Akademie Ved | Method for centrifugal casting a contact lens |
US3660545A (en) | 1961-12-27 | 1972-05-02 | Ceskoslovenska Akademie Ved | Method of centrifugally casting thin edged corneal contact lenses |
US4113224A (en) | 1975-04-08 | 1978-09-12 | Bausch & Lomb Incorporated | Apparatus for forming optical lenses |
US4197266A (en) | 1974-05-06 | 1980-04-08 | Bausch & Lomb Incorporated | Method for forming optical lenses |
US4436887A (en) | 1981-11-12 | 1984-03-13 | Bausch & Lomb Incorporated | N-Vinyl lactam based biomedical devices |
US4495313A (en) | 1981-04-30 | 1985-01-22 | Mia Lens Production A/S | Preparation of hydrogel for soft contact lens with water displaceable boric acid ester |
US4659782A (en) | 1984-07-05 | 1987-04-21 | E. I. Du Pont De Nemours And Company | Acrylic star polymers containing single-and multi-functional monomers in the core |
US4889664A (en) | 1988-11-25 | 1989-12-26 | Vistakon, Inc. | Method of forming shaped hydrogel articles including contact lenses |
US5006622A (en) | 1987-04-02 | 1991-04-09 | Bausch & Lomb Incorporated | Polymer compositions for contact lenses |
US5039459A (en) | 1988-11-25 | 1991-08-13 | Johnson & Johnson Vision Products, Inc. | Method of forming shaped hydrogel articles including contact lenses |
US5236969A (en) | 1987-04-02 | 1993-08-17 | Bausch & Lomb Incorporated | Polymer compositions for contact lenses |
US5244981A (en) | 1990-04-10 | 1993-09-14 | Permeable Technologies, Inc. | Silicone-containing contact lens polymers, oxygen permeable contact lenses and methods for making these lenses and treating patients with visual impairment |
US5270418A (en) | 1987-04-02 | 1993-12-14 | Bausch & Lomb Incorporated | Polymer compositions for contact lenses |
US5271875A (en) | 1991-09-12 | 1993-12-21 | Bausch & Lomb Incorporated | Method for molding lenses |
US5298533A (en) | 1992-12-02 | 1994-03-29 | Bausch & Lomb Incorporated | Polymer compositions for contact lenses |
US5314960A (en) | 1990-04-10 | 1994-05-24 | Permeable Technologies, Inc. | Silicone-containing polymers, oxygen permeable hydrophilic contact lenses and methods for making these lenses and treating patients with visual impairment |
US5371147A (en) | 1990-10-11 | 1994-12-06 | Permeable Technologies, Inc. | Silicone-containing acrylic star polymers, block copolymers and macromonomers |
US5760100A (en) | 1994-09-06 | 1998-06-02 | Ciba Vision Corporation | Extended wear ophthalmic lens |
US5776999A (en) | 1994-09-06 | 1998-07-07 | Ciba Vision Corporation | Methods of using and screening extended wear ophthalmic lenses |
US5824719A (en) | 1995-06-07 | 1998-10-20 | Bausch & Lomb Incorporated | Polymer compositions for contact lenses |
US5998498A (en) | 1998-03-02 | 1999-12-07 | Johnson & Johnson Vision Products, Inc. | Soft contact lenses |
US6087415A (en) | 1998-06-11 | 2000-07-11 | Johnson & Johnson Vision Care, Inc. | Biomedical devices with hydrophilic coatings |
US6367929B1 (en) | 1998-03-02 | 2002-04-09 | Johnson & Johnson Vision Care, Inc. | Hydrogel with internal wetting agent |
US6420453B1 (en) | 1990-10-29 | 2002-07-16 | Biocompatibles Limited | Contact lens material |
US6440366B1 (en) | 1997-06-06 | 2002-08-27 | Bausch & Lomb Incorporated | Contact lens packing solutions |
WO2003022321A2 (fr) | 2001-09-10 | 2003-03-20 | Johnson & Johnson Vision Care, Inc. | Dispositifs biomedicaux contenant des agents humidifiants internes |
US6767979B1 (en) | 1998-12-11 | 2004-07-27 | Biocompatibles Uk Limited | Crosslinked polymers and refractive devices formed therefrom |
US6822016B2 (en) | 2001-09-10 | 2004-11-23 | Johnson & Johnson Vision Care, Inc. | Biomedical devices containing internal wetting agents |
US6867245B2 (en) | 1999-12-16 | 2005-03-15 | Asahikasei Aime Co., Ltd. | Long wearable soft contact lens |
US6943203B2 (en) | 1998-03-02 | 2005-09-13 | Johnson & Johnson Vision Care, Inc. | Soft contact lenses |
US7247692B2 (en) | 2004-09-30 | 2007-07-24 | Johnson & Johnson Vision Care, Inc. | Biomedical devices containing amphiphilic block copolymers |
US7249848B2 (en) | 2004-09-30 | 2007-07-31 | Johnson & Johnson Vision Care, Inc. | Wettable hydrogels comprising reactive, hydrophilic, polymeric internal wetting agents |
US7262232B2 (en) | 2000-04-18 | 2007-08-28 | Coopervision, Inc. | Ophthalmic lenses and compositions and methods for producing same |
WO2008061992A2 (fr) | 2006-11-22 | 2008-05-29 | Sauflon Cl Limited | Lentille de contact |
US20080138310A1 (en) | 2006-12-11 | 2008-06-12 | Alcon Manufacturing, Ltd. | Use of PEO-PBO block copolymers in ophthalmic compositions |
US7431152B2 (en) | 2003-04-24 | 2008-10-07 | Coopervision International Holding Company, Lp | Hydrogel contact lenses and package systems and production methods for same |
US7553880B2 (en) | 1994-09-06 | 2009-06-30 | Ciba Vision Corporation | Extended wear ophthalmic lens |
US20090220618A1 (en) * | 2008-02-29 | 2009-09-03 | Erning Xia | Pharmaceutical formulations comprising polyanionic materials and source of hydrogen peroxide |
US20090239954A1 (en) * | 2008-03-19 | 2009-09-24 | Collins Gary L | Phosphate buffered ophthalmic solutions displaying improved efficacy |
US20100086514A1 (en) * | 2009-10-01 | 2010-04-08 | Liu X Michael | Contact Lens Care Solutions with a Low Molecular Weight Oligomer |
US7786185B2 (en) | 2004-03-05 | 2010-08-31 | Johnson & Johnson Vision Care, Inc. | Wettable hydrogels comprising acyclic polyamides |
US7841716B2 (en) | 2005-02-14 | 2010-11-30 | Johnson & Johnson Vision Care, Inc. | Comfortable ophthalmic device and methods of its production |
US7934830B2 (en) | 2007-12-03 | 2011-05-03 | Bausch & Lomb Incorporated | High water content silicone hydrogels |
US7956131B2 (en) | 2004-09-30 | 2011-06-07 | Johnson & Johnson Vision Care, Inc. | Lactam polymer derivatives |
US8053539B2 (en) | 2006-06-30 | 2011-11-08 | Johnson & Johnson Vision Care Inc. | Siloxanyl materials for molded plastics |
US8138290B2 (en) | 2008-01-25 | 2012-03-20 | Bausch & Lomb Incorporated | High water content ophthalmic devices |
US8399538B2 (en) | 1998-03-02 | 2013-03-19 | Johnson & Johnson Vision Care, Inc. | Contact lenses |
US8470906B2 (en) | 2008-09-30 | 2013-06-25 | Johnson & Johnson Vision Care, Inc. | Ionic silicone hydrogels having improved hydrolytic stability |
US8487058B2 (en) | 2011-02-28 | 2013-07-16 | Coopervision International Holding Company, Lp | Wettable silicone hydrogel contact lenses |
US8507577B2 (en) | 2006-10-31 | 2013-08-13 | Johnson & Johnson Vision Care, Inc. | Process for forming clear, wettable silicone hydrogel articles |
US8937110B2 (en) | 2011-12-23 | 2015-01-20 | Johnson & Johnson Vision Care, Inc. | Silicone hydrogels having a structure formed via controlled reaction kinetics |
US8937111B2 (en) | 2011-12-23 | 2015-01-20 | Johnson & Johnson Vision Care, Inc. | Silicone hydrogels comprising desirable water content and oxygen permeability |
US8940812B2 (en) | 2012-01-17 | 2015-01-27 | Johnson & Johnson Vision Care, Inc. | Silicone polymers comprising sulfonic acid groups |
US9057821B2 (en) | 2009-10-12 | 2015-06-16 | Sauflon Cl Limited | Method of making a contact lens |
US9056878B2 (en) | 2006-09-29 | 2015-06-16 | Johnson & Johnson Vision Care, Inc. | Hydrolysis-resistant silicone compounds |
US9125808B2 (en) | 2011-12-23 | 2015-09-08 | Johnson & Johnson Vision Care, Inc. | Ionic silicone hydrogels |
US9140825B2 (en) | 2011-12-23 | 2015-09-22 | Johnson & Johnson Vision Care, Inc. | Ionic silicone hydrogels |
US9156934B2 (en) | 2011-12-23 | 2015-10-13 | Johnson & Johnson Vision Care, Inc. | Silicone hydrogels comprising n-vinyl amides and hydroxyalkyl (meth)acrylates or (meth)acrylamides |
US9170349B2 (en) | 2011-05-04 | 2015-10-27 | Johnson & Johnson Vision Care, Inc. | Medical devices having homogeneous charge density and methods for making same |
US9244196B2 (en) | 2012-05-25 | 2016-01-26 | Johnson & Johnson Vision Care, Inc. | Polymers and nanogel materials and methods for making and using the same |
US9297929B2 (en) | 2012-05-25 | 2016-03-29 | Johnson & Johnson Vision Care, Inc. | Contact lenses comprising water soluble N-(2 hydroxyalkyl) (meth)acrylamide polymers or copolymers |
US9297928B2 (en) | 2004-11-22 | 2016-03-29 | Johnson & Johnson Vision Care, Inc. | Ophthalmic compositions comprising polyether substituted polymers |
US10371865B2 (en) | 2016-07-06 | 2019-08-06 | Johnson & Johnson Vision Care, Inc. | Silicone hydrogels comprising polyamides |
US10370476B2 (en) | 2016-07-06 | 2019-08-06 | Johnson & Johnson Vision Care, Inc. | Silicone hydrogels comprising high levels of polyamides |
US10935695B2 (en) | 2018-03-02 | 2021-03-02 | Johnson & Johnson Vision Care, Inc. | Polymerizable absorbers of UV and high energy visible light |
US20230037781A1 (en) | 2021-06-30 | 2023-02-09 | Johnson & Johnson Vision Care, Inc. | Transition metal complexes as visible light absorbers |
-
2023
- 2023-12-13 WO PCT/IB2023/062628 patent/WO2024134381A1/fr unknown
- 2023-12-13 WO PCT/IB2023/062625 patent/WO2024134380A1/fr unknown
Patent Citations (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3660545A (en) | 1961-12-27 | 1972-05-02 | Ceskoslovenska Akademie Ved | Method of centrifugally casting thin edged corneal contact lenses |
US3408429A (en) | 1963-09-11 | 1968-10-29 | Ceskoslovenska Akademie Ved | Method for centrifugal casting a contact lens |
US4197266A (en) | 1974-05-06 | 1980-04-08 | Bausch & Lomb Incorporated | Method for forming optical lenses |
US4113224A (en) | 1975-04-08 | 1978-09-12 | Bausch & Lomb Incorporated | Apparatus for forming optical lenses |
US4495313A (en) | 1981-04-30 | 1985-01-22 | Mia Lens Production A/S | Preparation of hydrogel for soft contact lens with water displaceable boric acid ester |
US4436887A (en) | 1981-11-12 | 1984-03-13 | Bausch & Lomb Incorporated | N-Vinyl lactam based biomedical devices |
US4659782A (en) | 1984-07-05 | 1987-04-21 | E. I. Du Pont De Nemours And Company | Acrylic star polymers containing single-and multi-functional monomers in the core |
US4659783A (en) | 1984-07-05 | 1987-04-21 | E. I. Du Pont De Nemours And Company | Acrylic star polymers containing multifunctional monomers in the core |
US5236969A (en) | 1987-04-02 | 1993-08-17 | Bausch & Lomb Incorporated | Polymer compositions for contact lenses |
US5006622A (en) | 1987-04-02 | 1991-04-09 | Bausch & Lomb Incorporated | Polymer compositions for contact lenses |
US5270418A (en) | 1987-04-02 | 1993-12-14 | Bausch & Lomb Incorporated | Polymer compositions for contact lenses |
US5039459A (en) | 1988-11-25 | 1991-08-13 | Johnson & Johnson Vision Products, Inc. | Method of forming shaped hydrogel articles including contact lenses |
US4889664A (en) | 1988-11-25 | 1989-12-26 | Vistakon, Inc. | Method of forming shaped hydrogel articles including contact lenses |
US5244981A (en) | 1990-04-10 | 1993-09-14 | Permeable Technologies, Inc. | Silicone-containing contact lens polymers, oxygen permeable contact lenses and methods for making these lenses and treating patients with visual impairment |
US5314960A (en) | 1990-04-10 | 1994-05-24 | Permeable Technologies, Inc. | Silicone-containing polymers, oxygen permeable hydrophilic contact lenses and methods for making these lenses and treating patients with visual impairment |
US5331067A (en) | 1990-04-10 | 1994-07-19 | Permeable Technologies, Inc. | Silicone-containing contact lens polymers, oxygen permeable contact lenses and methods for making these lenses and treating patients with visual impairment |
US5371147A (en) | 1990-10-11 | 1994-12-06 | Permeable Technologies, Inc. | Silicone-containing acrylic star polymers, block copolymers and macromonomers |
US6420453B1 (en) | 1990-10-29 | 2002-07-16 | Biocompatibles Limited | Contact lens material |
US6423761B1 (en) | 1990-10-29 | 2002-07-23 | Biocompatibles Limited | Contact lens material |
US5271875A (en) | 1991-09-12 | 1993-12-21 | Bausch & Lomb Incorporated | Method for molding lenses |
US5298533A (en) | 1992-12-02 | 1994-03-29 | Bausch & Lomb Incorporated | Polymer compositions for contact lenses |
US5760100B1 (en) | 1994-09-06 | 2000-11-14 | Ciba Vision Corp | Extended wear ophthalmic lens |
US7553880B2 (en) | 1994-09-06 | 2009-06-30 | Ciba Vision Corporation | Extended wear ophthalmic lens |
US5849811A (en) | 1994-09-06 | 1998-12-15 | Ciba Vision Corporation | Extended wear ophthalmic lens |
US5965631A (en) | 1994-09-06 | 1999-10-12 | Ciba Vision Corporation | Extended wear ophthalmic lens |
US5760100A (en) | 1994-09-06 | 1998-06-02 | Ciba Vision Corporation | Extended wear ophthalmic lens |
US5776999A (en) | 1994-09-06 | 1998-07-07 | Ciba Vision Corporation | Methods of using and screening extended wear ophthalmic lenses |
US5849811B1 (en) | 1994-09-06 | 2000-11-14 | Ciba Vision Corporatin | Extended wear ophthalmic lens |
US5789461A (en) | 1994-09-06 | 1998-08-04 | Ciba Vision Corporation | Methods of forming an extended wear ophthalmic lens having a hydrophilic surface |
US5776999B1 (en) | 1994-09-06 | 2000-11-21 | Ciba Vision Corp | Methods of using and screening extended wear opthalmic lenses |
US5789461B1 (en) | 1994-09-06 | 2000-11-21 | Ciba Vision Corp | Methods of forming an extended wear ophthalmic lens having a hydrophilic surface |
US5824719A (en) | 1995-06-07 | 1998-10-20 | Bausch & Lomb Incorporated | Polymer compositions for contact lenses |
US6440366B1 (en) | 1997-06-06 | 2002-08-27 | Bausch & Lomb Incorporated | Contact lens packing solutions |
US8399538B2 (en) | 1998-03-02 | 2013-03-19 | Johnson & Johnson Vision Care, Inc. | Contact lenses |
US6367929B1 (en) | 1998-03-02 | 2002-04-09 | Johnson & Johnson Vision Care, Inc. | Hydrogel with internal wetting agent |
US5998498A (en) | 1998-03-02 | 1999-12-07 | Johnson & Johnson Vision Products, Inc. | Soft contact lenses |
US6943203B2 (en) | 1998-03-02 | 2005-09-13 | Johnson & Johnson Vision Care, Inc. | Soft contact lenses |
US6087415A (en) | 1998-06-11 | 2000-07-11 | Johnson & Johnson Vision Care, Inc. | Biomedical devices with hydrophilic coatings |
US6767979B1 (en) | 1998-12-11 | 2004-07-27 | Biocompatibles Uk Limited | Crosslinked polymers and refractive devices formed therefrom |
US6867245B2 (en) | 1999-12-16 | 2005-03-15 | Asahikasei Aime Co., Ltd. | Long wearable soft contact lens |
US8637621B2 (en) | 1999-12-16 | 2014-01-28 | Coopervision International Holding Company, Lp | Long-wearable soft contact lens |
US7262232B2 (en) | 2000-04-18 | 2007-08-28 | Coopervision, Inc. | Ophthalmic lenses and compositions and methods for producing same |
US7666921B2 (en) | 2001-09-10 | 2010-02-23 | Johnson & Johnson Vision Care, Inc. | Biomedical devices containing internal wetting agents |
US6822016B2 (en) | 2001-09-10 | 2004-11-23 | Johnson & Johnson Vision Care, Inc. | Biomedical devices containing internal wetting agents |
US8450387B2 (en) | 2001-09-10 | 2013-05-28 | Johnson & Johnson Vision Care, Inc. | Biomedical devices containing internal wetting agents |
WO2003022321A2 (fr) | 2001-09-10 | 2003-03-20 | Johnson & Johnson Vision Care, Inc. | Dispositifs biomedicaux contenant des agents humidifiants internes |
US7431152B2 (en) | 2003-04-24 | 2008-10-07 | Coopervision International Holding Company, Lp | Hydrogel contact lenses and package systems and production methods for same |
US7786185B2 (en) | 2004-03-05 | 2010-08-31 | Johnson & Johnson Vision Care, Inc. | Wettable hydrogels comprising acyclic polyamides |
US8022158B2 (en) | 2004-03-05 | 2011-09-20 | Johnson & Johnson Vision Care, Inc. | Wettable hydrogels comprising acyclic polyamides |
US7247692B2 (en) | 2004-09-30 | 2007-07-24 | Johnson & Johnson Vision Care, Inc. | Biomedical devices containing amphiphilic block copolymers |
US7249848B2 (en) | 2004-09-30 | 2007-07-31 | Johnson & Johnson Vision Care, Inc. | Wettable hydrogels comprising reactive, hydrophilic, polymeric internal wetting agents |
US8273802B2 (en) | 2004-09-30 | 2012-09-25 | Johnson & Johnson Vision Care, Inc. | Wettable hydrogels comprising reactive, hydrophilic, polymeric internal wetting agents |
US7956131B2 (en) | 2004-09-30 | 2011-06-07 | Johnson & Johnson Vision Care, Inc. | Lactam polymer derivatives |
US9297928B2 (en) | 2004-11-22 | 2016-03-29 | Johnson & Johnson Vision Care, Inc. | Ophthalmic compositions comprising polyether substituted polymers |
US7841716B2 (en) | 2005-02-14 | 2010-11-30 | Johnson & Johnson Vision Care, Inc. | Comfortable ophthalmic device and methods of its production |
US8053539B2 (en) | 2006-06-30 | 2011-11-08 | Johnson & Johnson Vision Care Inc. | Siloxanyl materials for molded plastics |
US9056878B2 (en) | 2006-09-29 | 2015-06-16 | Johnson & Johnson Vision Care, Inc. | Hydrolysis-resistant silicone compounds |
US8507577B2 (en) | 2006-10-31 | 2013-08-13 | Johnson & Johnson Vision Care, Inc. | Process for forming clear, wettable silicone hydrogel articles |
US8703891B2 (en) | 2006-11-22 | 2014-04-22 | Sauflon Cl Limited | Contact lens |
US20100048847A1 (en) | 2006-11-22 | 2010-02-25 | Sauflon Cl Limited | Contact Lens |
WO2008061992A2 (fr) | 2006-11-22 | 2008-05-29 | Sauflon Cl Limited | Lentille de contact |
US8318144B2 (en) | 2006-12-11 | 2012-11-27 | Alcon Research, Ltd. | Use of PEO-PBO block copolymers in ophthalmic compositions |
US20080138310A1 (en) | 2006-12-11 | 2008-06-12 | Alcon Manufacturing, Ltd. | Use of PEO-PBO block copolymers in ophthalmic compositions |
US7934830B2 (en) | 2007-12-03 | 2011-05-03 | Bausch & Lomb Incorporated | High water content silicone hydrogels |
US8389597B2 (en) | 2008-01-25 | 2013-03-05 | Bausch & Lomb Incorporated | High water content ophthalmic devices |
US8138290B2 (en) | 2008-01-25 | 2012-03-20 | Bausch & Lomb Incorporated | High water content ophthalmic devices |
US20090220618A1 (en) * | 2008-02-29 | 2009-09-03 | Erning Xia | Pharmaceutical formulations comprising polyanionic materials and source of hydrogen peroxide |
US20090239954A1 (en) * | 2008-03-19 | 2009-09-24 | Collins Gary L | Phosphate buffered ophthalmic solutions displaying improved efficacy |
US8470906B2 (en) | 2008-09-30 | 2013-06-25 | Johnson & Johnson Vision Care, Inc. | Ionic silicone hydrogels having improved hydrolytic stability |
US9260544B2 (en) | 2008-09-30 | 2016-02-16 | Johnson & Johnson Vision Care, Inc. | Ionic silicone hydrogels having improved hydrolytic stability |
US20100086514A1 (en) * | 2009-10-01 | 2010-04-08 | Liu X Michael | Contact Lens Care Solutions with a Low Molecular Weight Oligomer |
US9057821B2 (en) | 2009-10-12 | 2015-06-16 | Sauflon Cl Limited | Method of making a contact lens |
US8487058B2 (en) | 2011-02-28 | 2013-07-16 | Coopervision International Holding Company, Lp | Wettable silicone hydrogel contact lenses |
US9170349B2 (en) | 2011-05-04 | 2015-10-27 | Johnson & Johnson Vision Care, Inc. | Medical devices having homogeneous charge density and methods for making same |
US9244197B2 (en) | 2011-12-23 | 2016-01-26 | Johnson & Johnson Vision Care, Inc. | Silicone hydrogels comprising desirable water content and oxygen permeability |
US9140825B2 (en) | 2011-12-23 | 2015-09-22 | Johnson & Johnson Vision Care, Inc. | Ionic silicone hydrogels |
US9156934B2 (en) | 2011-12-23 | 2015-10-13 | Johnson & Johnson Vision Care, Inc. | Silicone hydrogels comprising n-vinyl amides and hydroxyalkyl (meth)acrylates or (meth)acrylamides |
US9125808B2 (en) | 2011-12-23 | 2015-09-08 | Johnson & Johnson Vision Care, Inc. | Ionic silicone hydrogels |
US8937110B2 (en) | 2011-12-23 | 2015-01-20 | Johnson & Johnson Vision Care, Inc. | Silicone hydrogels having a structure formed via controlled reaction kinetics |
US8937111B2 (en) | 2011-12-23 | 2015-01-20 | Johnson & Johnson Vision Care, Inc. | Silicone hydrogels comprising desirable water content and oxygen permeability |
US8940812B2 (en) | 2012-01-17 | 2015-01-27 | Johnson & Johnson Vision Care, Inc. | Silicone polymers comprising sulfonic acid groups |
US9297929B2 (en) | 2012-05-25 | 2016-03-29 | Johnson & Johnson Vision Care, Inc. | Contact lenses comprising water soluble N-(2 hydroxyalkyl) (meth)acrylamide polymers or copolymers |
US9244196B2 (en) | 2012-05-25 | 2016-01-26 | Johnson & Johnson Vision Care, Inc. | Polymers and nanogel materials and methods for making and using the same |
US10371865B2 (en) | 2016-07-06 | 2019-08-06 | Johnson & Johnson Vision Care, Inc. | Silicone hydrogels comprising polyamides |
US10370476B2 (en) | 2016-07-06 | 2019-08-06 | Johnson & Johnson Vision Care, Inc. | Silicone hydrogels comprising high levels of polyamides |
US10935695B2 (en) | 2018-03-02 | 2021-03-02 | Johnson & Johnson Vision Care, Inc. | Polymerizable absorbers of UV and high energy visible light |
US20210109255A1 (en) | 2018-03-02 | 2021-04-15 | Johnson & Johnson Vision Care, Inc. | Polymerizable absorbers of uv and high energy visible light |
US20230037781A1 (en) | 2021-06-30 | 2023-02-09 | Johnson & Johnson Vision Care, Inc. | Transition metal complexes as visible light absorbers |
Non-Patent Citations (3)
Title |
---|
C, LABBEA, LIANGH, PAULYA, BRIGNOLE-BAUDOUIN F.: "Preservatives in eyedrops: the good, the bad and the ugly", PROG RETIN EYE RES., vol. 29, no. 4, July 2010 (2010-07-01), pages 312 - 34, XP055616054, DOI: 10.1016/j.preteyeres.2010.03.001 |
PANKEY, G.A.SABATH, L.D: "Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections", CLINICAL INFECTIOUS DISEASES, vol. 38, 2004, pages 864 - 870 |
ROBINSON, H., W.: "The Influence of Neutral Salts on the pH of Phosphate Buffer Mixtures", J. BIOL. CHEM., no. 3, 1929, pages 775 - 802 |
Also Published As
Publication number | Publication date |
---|---|
WO2024134380A1 (fr) | 2024-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7247270B2 (en) | Method and composition for reducing contact lens swelling | |
EP1734923B1 (fr) | Composition de conservateur a base de zinc et procede d'utilisation | |
JP2011515393A (ja) | 改善された有効性を示すリン酸塩緩衝眼科用溶液 | |
US20050124700A1 (en) | Biguanide/quaternary ammonium containing copolymeric biocides and use thereof in pharmaceutical compositions | |
US9512385B2 (en) | Disinfectant solution for nonionic soft contact lenses | |
EP2936215B1 (fr) | Lentilles de contact ophtalmiques antimicrobiennes | |
WO2024134381A1 (fr) | Compositions pour dispositifs ophtalmologiques | |
US20060276359A1 (en) | Composition and method for cleaning lipid deposits on contact lenses | |
WO2024134384A1 (fr) | Compositions pour dispositifs ophtalmologiques | |
AU2022200172B2 (en) | Compositions for ophthalmologic devices | |
WO2024134383A1 (fr) | Compositions pour dispositifs ophtalmologiques | |
WO2024134382A1 (fr) | Compositions pour dispositifs ophtalmologiques | |
US20240159938A1 (en) | Compositions for Ophthalmologic Devices | |
NZ784167A (en) | Compositions for ophthalmologic device | |
US20050124702A1 (en) | Use of organic buffering agents to enhance the antimicrobial activity of pharmaceutical compositions |